

Mapping Pharmacologically-induced Functional Reorganisation onto the Brain's Neurotransmitter Landscape

Andrea I. Luppi^{1,2,3,4*}, Justine Y. Hansen⁵, Ram Adapa¹, Robin L. Carhart-Harris⁶, Leor Roseman⁷, Christopher Timmermann⁷, Daniel Golkowski⁸, Andreas Ranft⁹, Rüdiger Ilg^{8,10}, Denis Jordan¹¹, Vincent Bonhomme^{12,13}, Audrey Vanhaudenhuyse¹², Athena Demertzi¹⁴, Oceane Jaquet¹², Mohamed Ali Bahri¹⁴, Naji L.N. Alnagger¹², Paolo Cardone¹², Alexander R. D. Peattie^{1,2}, Anne E. Manktelow¹, Draulio B. de Araujo¹⁵, Stefano L. Sensi^{16,17}, Adrian M. Owen¹⁸, Lorina Naci¹⁹, David K. Menon^{1,20}, Bratislav Misic⁵, Emmanuel A. Stamatakis^{1,2}

¹Division of Anaesthesia, University of Cambridge, Cambridge, UK.

²Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

³Leverhulme Centre for the Future of Intelligence, University of Cambridge, Cambridge, UK.

⁴The Alan Turing Institute, London, UK.

⁵McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

⁶Psychedelics Division - Neuroscape, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

⁷Center for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK.

⁸Department of Neurology, Klinikum rechts der Isar, Technical University Munich, München, Germany.

⁹Technical University of Munich, School of Medicine, Department of Anesthesiology and Intensive Care, Munich, Germany.

¹⁰Asklepios Clinic, Department of Neurology, Bad Tölz, Germany.

¹¹Department of Anaesthesiology and Intensive Care Medicine, Klinikum rechts der Isar, Technical University Munich, München, Germany.

¹²Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium.

¹³Anesthesia and Perioperative Neuroscience Laboratory, GIGA-Consciousness Thematic Unit, GIGA-Research, Liege University, Liege, Belgium.

¹⁴GIGA-Cyclotron Research Centre-In Vivo Imaging, University of Liege, Liege, Belgium.

¹⁵Brain Institute, Federal University of Rio Grande do Norte, Natal, RN, Brazil.

¹⁶Department of Neuroscience and Imaging and Clinical Science, Center for Advanced Studies and Technology, Institute for Advanced Biomedical Technologies, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.

¹⁷Institute for Memory Impairments and Neurological Disorders, University of California-Irvine, Irvine, CA, USA.

¹⁸Department of Psychology and Department of Physiology and Pharmacology, Western Institute for Neuroscience (WIN), Western University, London, ON, Canada.

¹⁹Trinity College Institute of Neuroscience, School of Psychology, Trinity College Dublin, Dublin, Ireland.

²⁰Wolfon Brain Imaging Centre, University of Cambridge, Cambridge, UK.

*Corresponding author: email: al857@cam.ac.uk

Abstract

To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain's rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically-induced macroscale functional reorganisation, by relating the regional distribution of 19 neurotransmitter receptors and transporters obtained from Positron Emission Tomography, and the regional changes in functional MRI connectivity induced by 10 different mind-altering drugs: propofol, sevoflurane, ketamine, LSD, psilocybin, DMT, ayahuasca, MDMA, modafinil, and methylphenidate. Our results reveal that psychoactive drugs exert their effects on brain function by engaging multiple neurotransmitter systems. The effects of both anaesthetics and psychedelics on brain function are organised along hierarchical gradients of brain structure and function. Finally, we show that regional co-susceptibility to pharmacological interventions recapitulates co-susceptibility to disorder-induced structural alterations. Collectively, these results highlight rich statistical patterns relating molecular chemoarchitecture and drug-induced reorganisation of the brain's functional architecture.

Keywords: neurotransmitters; receptors; functional MRI; pharmacology; anaesthesia; psychedelic; cognitive enhancer; Positron Emission Tomography.

Introduction

Understanding how the brain orchestrates complex signals across spatial and temporal scales to support cognition and consciousness is a fundamental challenge of contemporary neuroscience. By inducing profound but reversible alterations of brain function, psychoactive compounds provide neuroscientists with the means to manipulate the brain without requiring surgical intervention. In combination with non-invasive brain imaging techniques such as functional MRI, acute pharmacological interventions have therefore emerged as a prominent tool for causal investigation of the relationship between brain and cognitive function in healthy humans¹.

Mind-altering pharmacological agents also play a fundamental role in modern clinical practice. The invention of anaesthesia was a major milestone in medical history, enabling millions of life-saving surgeries to take place every year². Other drugs that influence the mind without suppressing consciousness, such as the cognitive enhancers modafinil and methylphenidate, have found useful applications in alleviating the cognitive symptoms of syndromes such as ADHD, narcolepsy, and traumatic brain injury (TBI)^{3–11}. More recently, classic and “atypical” psychedelics are increasingly being investigated for their potential to provide breakthrough avenues to treat psychiatric conditions, with recent successes in clinical trials heralding a possible end to the current scarcity of therapies for treatment-resistant depression and other neuropsychiatric disorders^{12–17}. For these convergent reasons, the effects of anaesthetics, psychedelics, and cognitive enhancers on brain function are becoming the focus of intense investigation, revealing both similarities and differences between them^{18–26}.

Pharmacological agents exert their mind-altering effects by tuning the brain’s neurotransmitter landscape. Neurotransmitters engage receptors on neurons’ membrane to mediate the transfer and propagation of signals between cells, modulate the functional configurations of neuronal circuits, and ultimately shape network-wide communication^{27–31}. Several psychoactive drugs appear to exert their effects on the mind and brain primarily through one or few specific neurotransmitters: the main action of the general anaesthetic propofol is enhancement of synaptic transmission mediated by GABA-A receptors, a mechanism that is also shared by

sevoflurane, which in addition attenuates glutamatergic synaptic signalling (mediated by both AMPA and NMDA receptors)^{2,32–39}. Ketamine (a dissociative anaesthetic at high doses, and atypical psychedelic at low doses) is an NMDA receptor antagonist^{40–45}; the classic psychedelics LSD, psilocybin, and DMT are agonists of the serotonin 2A receptor, with a strong dependence between subjective efficacy and 2A receptor affinity^{46–49}.

However, in the words of Sleight and colleagues, “Linking observed molecular actions for any particular drug with its clinical effects is an abiding pharmacological problem”⁵⁰: knowing the primary molecular target is not sufficient to understand a drug’s effects on brain function, for several reasons. First, given the brain’s intricate, nested feedback loops and recurrent pathways of connectivity, even a relatively selective drug can end up influencing unrelated systems beyond what may be apparent from in vitro studies. Second, most mind-altering compounds are also known to have affinity for other receptors. Indeed, evidence has been accumulating that multiple neurotransmitter influences may be involved in both the neural and subjective experiences induced by many consciousness-altering drugs. In the last year, human neuroimaging studies identified the involvement of the dopaminergic system in both propofol-induced anaesthesia⁵¹ and the subjective effects of LSD⁵². More broadly, a recent large-scale study, combining receptor expression from transcriptomic data with linguistic processing of several thousand subjective reports of psychedelic use, identified complex multivariate patterns of association between neurotransmitters and their effects on the mind elicited by a wide variety of psychedelics, even for putatively selective agents⁵³. At the same time, molecularly different compounds can exert intriguingly similar effects on both the mind and brain: for instance, LSD and (sub-anaesthetic) ketamine can produce subjectively similar effects and changes in terms of structure-function coupling and the complexity of brain activity - despite acting on different pathways²¹. This suggests both divergent and convergent effects of different pharmacological agents on the brain’s rich neurotransmitter landscape.

Finally, the human brain exhibits rich patterns of anatomical, functional, cytoarchitectonic, and molecular variations^{54–59}. Such patterns also extend to the regional distribution of different neurotransmitter receptors and transporters, which

vary widely not only in terms of their affinity, time-scales, and downstream effects on neuronal excitability, but also their distribution across regions, layers and neuron types^{27–30}. Therefore, our knowledge of how a drug influences neurotransmission must take into account the neuroanatomical distribution of its target neurotransmitters - an essential step towards explaining how different neurotransmitters mediate the capacity of different drugs to shape the functional and computational properties of the brain's architecture^{27,31}.

Here, we sought to address this question in a data-driven way, mapping the neurotransmitter landscape of drug-induced alterations in the brain's functional connectivity. To do so, we leveraged two unique datasets: (i) a recently assembled collection of in vivo maps of regional receptor expression from 19 different receptors, obtained from PET scanning of over 1200 total subjects, providing the most detailed information about neuromodulators and their spatial distribution available to date³¹; and (ii) resting-state functional MRI (rs-fMRI) data acquired under the effects of the serotonergic psychedelics LSD⁶⁰, psilocybin⁶¹, DMT (Timmermann *et al.*, under review), ayahuasca⁶², and MDMA⁶³; sub-anaesthetic doses of ketamine (acting as an “atypical psychedelic”)⁶⁴ as well as anaesthetic doses (acting as a “dissociative anaesthetic”); the cognitive enhancers modafinil⁶⁵ and methylphenidate¹⁰; and the anaesthetics sevoflurane⁶⁶ and propofol^{67,68} (which we compared against pre-anaesthetic baseline as well as post-anaesthetic recovery); representing a total of 382 sessions of pharmacological-MRI from 224 distinct subjects and 10 distinct pharmacological agents. Through pharmacologically modulated rs-fMRI, we can characterise a drug's effects on the brain's spontaneous activity, without the interference of any specific task¹.

Thus, our goal was to obtain a comprehensive mapping between the cortical distributions of neurotransmitters and a set of diverse psychoactive pharmacological agents (covering the range from anaesthetics to psychedelics), in terms of their effects of functional connectivity. There have been other studies looking at the relationships between brain changes induced by one or few psychoactive drugs, and one or few neurotransmitter systems^{51,52,69–74} – and a previous effort considering how changes in cerebral blood flow induced by different psychiatric medications depend on the distribution of receptors⁷⁵. However, to our knowledge, this is the largest fMRI

study to date not only in terms of the number, variety, and potency of psychoactive pharmacological agents included, but also the breadth and coverage of neurotransmitter systems considered.

Results

To establish a relationship between neurotransmitter systems and pharmacologically-induced reorganisation of the brain's functional architecture, we combine two sets of neuroimaging data, each collected from across multiple studies. On one hand, we characterise drug-induced functional reorganisation as the changes in functional connectivity (FC) obtained by contrasting resting-state functional MRI (rs-fMRI) at baseline and under the acute effect of a psychoactive drug. We considered the general anaesthetics propofol (two independent datasets) and sevoflurane; the cognitive enhancers modafinil and methylphenidate; ketamine, acting as both atypical psychedelic (at sub-anaesthetic doses) and as dissociative anaesthetic^{24,75,76}; and the serotonergic psychedelics lysergic acid diethylamide (LSD), psilocybin, DMT, ayahuasca, and MDMA (Figure 1). For sevoflurane and both propofol datasets, we considered two contrasts: drug versus pre-induction baseline, and drug versus post-anaesthetic recovery (recovery data were not available for ketamine). We followed the same preprocessing and denoising procedure for each dataset, to ensure comparability (see Methods).

On the other hand, we consider the cortical distribution of 15 neurotransmitter receptors and 4 transporters, obtained from in vivo Positron Emission Tomography³¹. Overall, 9 neurotransmitter and neuromodulatory systems ("neurotransmitters" for short) are covered: dopamine (D1⁷⁷, D2^{78–81}, DAT⁸²), norepinephrine (NET^{83–86}), serotonin (5-HT1A⁸⁷, 5-HT1B^{87–90,90–92}, 5-HT2A⁹³, 5-HT4⁹³, 5-HT6^{94,95}, 5-HTT⁹³), acetylcholine ($\alpha 4\beta 2$ ^{96,97}, M1⁹⁸, VACHT^{99,100}), glutamate (mGluR5^{101,102}, NMDA^{103,104}), GABA (GABA-A¹⁰⁵), histamine (H3¹⁰⁶), cannabinoid (CB1^{107–110}), and opioid (MOR¹¹¹). (Figure 1A,B). Both rs-fMRI and PET maps were parcellated into 100 functionally defined regions according to the Schaefer atlas¹¹².




Figure 1. Overview of receptors and pharmacological rs-fMRI data. (A) For each psychoactive drug, its pattern of pharmacologically-induced functional reorganisation is quantified as the average (across subjects) of the within-subject difference in regional FC density between task-free fMRI scans at baseline and under the drug's effects. The result is a map of 100 cortical regions by 15 drug-related contrasts. (B) Neurotransmitter systems are mapped with Positron Emission Tomography with radioligands for 15 receptors and 4 transporters, resulting in a map of 100 cortical regions by 19 neurotransmitters. Correlating each of these sets of maps against itself yields two region-by-region matrices of pharmacological co-susceptibility (C) and neurotransmitter co-expression (D), respectively, which are significantly correlated even after removing the exponential relationship with Euclidean distance between regions (E).

Brain regions with shared chemoarchitecture also respond similarly across pharmacological perturbations

Receptors and transporters shape the way that neurons respond to neurotransmission and neuromodulatory influences. In turn, psychoactive drugs exert their effects (primarily) by acting on neurotransmitters and neuromodulators. Therefore, we reasoned that everything else being equal, regions that express similar patterns of receptors and transporters should exhibit similar patterns of susceptibility to drug-induced functional reorganisation.

To address this question, we computed matrices of pharmacological co-susceptibility and neurotransmitter co-expression between pairs of regions, by correlating respectively the regional patterns of drug-induced FC changes (across all subjects), and the regional patterns of neurotransmitter expression across all 19 receptor and transporter PET maps. To account for spatial autocorrelation in molecular and FC attributes, we regressed out from both matrices the exponential trend with Euclidean distance^{113–116}.

Supporting our hypothesis, we found that pharmacological co-susceptibility is significantly correlated with neurotransmitter profile similarity: the extent to which two regions' FC patterns are similarly affected by perturbations induced by different psychoactive drugs, is predicted by the extent to which they co-express neurotransmitter receptors and transporters: $\rho = 0.34$, $p < 0.001$ after regressing out the effects of Euclidean distance (Figure 1C-E). In other words, regions that exhibit shared chemoarchitecture also respond similarly across pharmacological perturbations.

254

255 Multivariate Receptor-Drug Associations

256

257 The previous analysis revealed of a relationship between large-scale patterns of
 258 neurotransmitter expression, and large-scale patterns of functional susceptibility to
 259 pharmacological perturbations – complementing previous work that identified
 260 relationships between individual drugs and individual receptors. However, neither of
 261 these two approaches captures the full richness of the two datasets employed here.
 262 To obtain a synthesis between these two approaches, we employed a multivariate
 263 association technique, Partial Least Squares correlation (PLS, also known as
 264 Projection to Latent Structures^{117,118}), which enabled us to identify multivariate
 265 patterns of maximum covariance between drug-induced effects on functional
 266 connectivity, and the cortical distributions of neurotransmitter expression^{119,120}.

267

268 This analysis indicated the presence of two statistically significant latent variables
 269 (linear weighted combinations of the original variables) relating pharmacologically-
 270 induced functional reorganisation to neurotransmitter profiles, together accounting
 271 for nearly 85% of covariance. Significance was assessed against autocorrelation-
 272 preserving spin-based null models, embodying the null hypothesis that drug effects
 273 and neurotransmitters are spatially correlated with each other purely because of
 274 inherent spatial autocorrelation^{121–124} (Figure 2). We further cross-validated this
 275 result using a distance-dependent method; out-of-sample $r = 0.46$ for PLS1 and 0.54
 276 for PLS2, both $p < 0.001$ from t-test against spin-based null distributions) (Figure
 277 S1).

278

279




Figure 2. PLS analysis reveals spatially covarying patterns of pharmacologically-induced functional reorganisation and neurotransmitter expression. (A) PLS analysis relates two data domains by correlating the variables across brain regions and subjecting this to singular value decomposition. This results in multiple latent variables: linear weighted combinations of the original variables (neurotransmitter weights and drug weights) that maximally covary with each other. (B) Latent variables are ordered according to effect size (the proportion of covariance explained between neurotransmitter expression and drug-induced functional reorganisation they account for) and shown as red dots. (C) The first two latent variables (PLS1 and PLS2) were statistically significant, with respect to the spatial autocorrelation-preserving null model shown in grey (10,000 permutations). The first latent variable accounted for 57% of covariance, and the second latent variable accounted for 28%. Neurotransmitter (drug) scores are defined as the projection of the original neurotransmitter density (drug-induced FC changes) matrix onto the neurotransmitter (drug) weights, such that each brain region is associated with a neurotransmitter and drug score. By design, neurotransmitter and drug scores correlate highly.

For each latent variable, each brain region is associated with a neurotransmitter and drug score. In turn, neurotransmitter (drug) loadings are defined as the correlation between the PLS-derived score pattern and each neurotransmitter's density of expression (resp., drug-induced FC changes) across brain regions. Taking into account the first latent variable (PLS1), drug loadings showed a distinction of

pharmacological effects into two groups, with all anaesthetics (except ketamine) on one side, and both ketamine datasets dominating the opposite side, together with LSD, ayahuasca, and modafinil (Figure 3A). Neurotransmitter loadings divided the receptors from transporters: at the positive end (orange), the noradrenaline, serotonin and acetylcholine transporters (with the dopamine transporter following closely, but narrowly including zero in its 95% CI); all receptors except NMDA were instead at the negative end (blue), although some included zero in their CI (Figure 3B).




Figure 3. PLS scores and loadings from significant latent variables. (A-B) Scores and loadings for PLS1. (C-D) scores and loadings for PLS2. Brain plots: Drug scores (top row) and neurotransmitter scores (bottom row) for each brain region are obtained by projecting the original neurotransmitter and drug data back onto the PLS analysis-defined drug/neurotransmitter weights, indexing the extent to which a brain region expresses covarying drug/ neurotransmitter patterns. In turn, neurotransmitter (drug) loadings are defined as the Pearson's correlation between each neurotransmitter's density of expression (drug-induced FC changes) across brain regions and the PLS analysis-derived score pattern. Error bars indicate 95% confidence interval, and colour indicates direction of the effect: positive (orange), negative (blue), or null (grey). Same-coloured loadings and scores co-vary positively, whereas opposite-coloured drugs and scores co-vary negatively. The label "ketamine 1" refers to the sub-anaesthetic dose, and "ketamine 2" is the anaesthetic dose.

Pertaining to the second latent variable (PLS2), neurotransmitter loadings mainly identified a monoamine-rich end (with dopamine and serotonin), although 5-HT1b occupied the opposite end. However, the drug loadings were less clearly discernible, with modafinil alone at one end, and a mixture of propofol, psychedelics, and both ketamine datasets at the other end. Both neurotransmitter and drug scores markedly separated dorsal and ventral aspects of the brain for this second latent variable (Figure 3).

Pharmacologically-induced alterations align with functional, anatomical and molecular hierarchies

Neurotransmitter and drug scores (whose spatial similarity PLS is designed to maximise) provide information about the regional distribution of neurotransmitter-drug associations. Neurotransmitters and drugs whose activity correlates positively with the score pattern covary with one another in the positively scored regions, and vice versa for negatively scored regions.

PLS1 scores correspond to the main axis of covariance between neurotransmitter expression and pharmacologically-induced functional reorganisation. For both drug and receptor scores, we observed that their regional distribution reflected the brain's organisation into intrinsic resting-state networks (RSNs)¹²⁵, setting apart visual and somatomotor cortices from association cortices (Figures 3,4). It is possible that the correspondence of PLS1 scores with RSNs may be in part driven by the fact that these networks are predicated in terms of functional neuroimaging, which we also used to characterise drug-induced functional reorganisation in our data. Therefore, we next sought to determine whether our data-driven topographic patterns reflect other cortical gradients of variation in terms of functional, anatomical, and molecular attributes. To this end, we considered intracortical myelination obtained from T1w/T2w MRI ratio⁵⁸; evolutionary cortical expansion obtained by comparing human and macaque¹²⁶; the principal component of variation in gene expression from the Allen Human Brain Atlas transcriptomic database ("AHBA PC1")^{59,127}; the principal component of variation in task activation from the NeuroSynth database ("NeuroSynth PC1")^{59,128}; and the principal gradient of functional connectivity⁵⁷.

Since pharmacological interventions exert their effects on the brain via the bloodstream, we also included a map of cerebral blood flow⁵⁴. Finally, we included a recently derived gradient of regional prevalence of different kinds of information, from redundancy to synergy¹²⁹.

We observed significant correlations (assessed against spin-based null models) between each cortical hierarchy and both neurotransmitter and drug scores for PLS1 (except for PLS1 drug scores versus NeuroSynth PC1; $p_{spin} = 0.054$) (Figure 4). The scores for PLS2 instead identified a ventral-dorsal pattern of regional variation (Figure 3 and Figure S2), which did not significantly correlate with any of the canonical gradients of hierarchical organisation (all $p > 0.05$ against spin-based null models, except for PLS2 drug scores versus NeuroSynth PC1; $p_{spin} = 0.013$).




Figure 4. Correspondence between the principal axis of drug-neurotransmitter scores and functional, anatomical and molecular hierarchies. (A) Cortical distribution of drug scores for PLS1, and their association with intrinsic resting-state networks. (B) Radial plot represents the absolute value of the correlation between PLS1 drug and neurotransmitter scores, and each of seven cortical hierarchies obtained from different neuroimaging modalities (note that the myelin and AHBA PC1 maps are reversed with respect to the remaining hierarchies).

Neurotransmitter landscape of pharmacologically-induced functional reorganisation

Taking into account the first two PLS latent variables shows how each drug-specific pattern of pharmacologically-induced functional reorganisation can be interpreted in

terms of contributions from different receptors (note that sign is arbitrary) (Figure 5). As already shown in Figure 3, the first latent variable revealed a stark division between transporters and receptors, which discriminates between traditional anaesthetics and other psychoactive substances. In terms of pharmacological alterations, the non-monoaminergic end of the second latent variable loaded onto drugs with relatively stronger effects on subjective experiences (the higher doses of anaesthetic, including ketamine, and LSD and MDMA). However, methylphenidate and sub-anaesthetic ketamine also loaded onto this end of the second latent variable. Altogether, we find that the first latent variable captures a strong relationship between drug interventions and receptor systems that is both biologically relevant and aligns with the functional organisation of the brain.




Figure 5. Biplot of neurotransmitters and pharmacological agents. Each drug is represented as a point reflecting its projection onto the first two latent variables of the PLS analysis, color-coded based on its effects on subjective experience (anaesthetic, psychedelic, or other psychoactive). Each neurotransmitter receptor and transporter is represented as a vector in the same 2D space, color-coded by loading onto PLS1 as shown in Figure 3 (orange for positive; blue for negative; and grey if the 95% CI intersects zero). For both propofol (Ppfl) and ketamine (keta), the number refers to the dataset, with 1 identifying the weaker dose, and 2 identifying the stronger dose. Figure S3 shows the drugs and neurotransmitters separately.

Co-susceptibility to pharmacological and pathological alterations

Finally, we wondered if the functional co-susceptibility of different regions to transient pharmacological perturbations may provide a functional proxy for their co-susceptibility to structural perturbations resulting from different neurological, neurodevelopmental, and psychiatric disorders. To this end, we combined 11 spatial maps of cortical thickness abnormalities made available by the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) consortium¹³⁰: 22q11.2 deletion syndrome¹³¹, attention-deficit/hyperactivity disorder¹³², autism spectrum disorder¹³³, idiopathic generalized epilepsy¹³⁴, right temporal lobe epilepsy¹³⁴, left temporal lobe epilepsy¹³⁴, depression¹³⁵, obsessive-compulsive disorder¹³⁶, schizophrenia¹³⁷, bipolar disorder¹³⁸, and Parkinson's disease¹³⁹. For simplicity, we refer to diseases, disorders, and conditions as “disorders” throughout the text. The cortical abnormality maps summarise contrasts between over 21,000 adult patients and 26,000 controls, collected following identical processing protocols to ensure maximal comparability¹³⁰.

Following the same procedure used to obtain the region x region matrices of pharmacological co-susceptibility and neurotransmitter co-expression in Figure 1, we obtained a region x region matrix of co-susceptibility to disorder-induced cortical abnormality by correlating the regional patterns of cortical abnormality across all 11 disorders¹¹³ (Figure 6A,B). Correlating this matrix of regional co-susceptibility to disease-associated perturbations against the previously derived matrix of regional co-susceptibility to pharmacological perturbations, we found a statistically significant relationship (Spearman's $\rho = 0.31$, $p < 0.001$ after regressing out the effect of Euclidean distance) (Figure 6C). This result goes beyond a recent demonstration that molecular similarity and disorder similarity are correlated¹¹³, by showing that a

correlation also exists between different kinds of perturbations: anatomical and pharmacological.

This observation suggests that there may be common patterns of regional co-susceptibility to perturbations, whether structural or functional. To explore this possibility explicitly, we resorted to a non-linear dimensionality reduction algorithm, diffusion map embedding^{57,140}, to obtain joint gradients of variation from pharmacological and disease-associated co-susceptibility using a recently developed method for network fusion¹⁴¹. We found that the main axis of variation in regional joint susceptibility to pharmacological and neuropsychiatric alterations corresponds to the well-known principal gradient of functional connectivity⁵⁷, setting apart unimodal from transmodal cortices, reminiscent of the PLS1 scores (Figure 6D). The second gradient instead sets apart anterior dorsal and more ventral parts of the brain, reminiscent of the PLS2 scores (Figure 6E). Together, these two gradients account for nearly half of the variation in regional co-susceptibility (Figure 6F).

When applying diffusion map embedding to the matrix of pharmacological co-susceptibility only, we found that the first two gradients of variation in regional pharmacological susceptibility coincide with the two principal gradients of functional connectivity of Margulies *et al*⁵⁷ (Figure S4): the first gradient sets apart unimodal from transmodal cortices, coinciding with the first gradient of joint susceptibility, whereas the second gradient is anchored in visual cortex at one end, and somatomotor cortex at the other end. This observation suggests that co-susceptibility to pharmacological perturbations recapitulates intrinsic functional architecture, as well as the co-susceptibility to disorder-induced structural perturbations.




Figure 6. Co-susceptibility to pharmacological and pathological alterations. Brain regions that are similarly affected by pharmacology, in terms of functional reorganisation (A) are also similarly affected across disorders (B), in terms of cortical thickness abnormalities. This relationship persists after regressing out the exponential trend with Euclidean distance (C). (D-E) First two principal gradients of regional joint susceptibility to pharmacological and neuropsychiatric and neurological alterations, obtained from diffusion map embedding. (F) Scree plot of the scaled eigenvalues from diffusion map embedding versus number of components.

Validation and additional analyses

Results for a different cortical parcellation (Lausanne-114¹⁴²) are provided as Supplementary Information (Figures S5, S6); likewise, we show a qualitatively similar mapping between drugs and neurotransmitters on the first two latent variables, even when the methylphenidate dataset (obtained from patients rather than healthy controls) is excluded (Figure S7).

We also performed a separate PLS analysis on the subcortex, which revealed a monoamine- (dopamine- and serotonin-) dominated principal latent variable, positively associated with the drugs having strongest effects, and separating caudate, putamen, and anterior thalamus from posterior thalamus, hippocampus and amygdala (Figure S8).

Discussion

Here, we characterised how mind-altering pharmacological agents engage the brain's rich neurotransmitter landscape to exert their effects on brain function. We mapped the functional chemoarchitecture of the human brain, by developing a computational framework to relate the regional reorganisation of fMRI functional connectivity induced by 10 different mind-altering drugs, and the cortical distribution of 19 neurotransmitter receptors and transporters obtained from PET³¹. This approach allowed us to discover large-scale spatial gradients relating pharmacologically-induced changes in functional connectivity to the underlying neurotransmitter systems. By relating microscale molecular chemoarchitecture and macroscale functional reorganisation induced by drugs with potent acute effects on the mind, our results provide a first step to bridge molecular mechanisms and their effects on subjective experience, cognition, and behaviour, via their effects on the brain's functional architecture.

Using our computational framework, we found that psychoactive drugs are best understood in terms of contributions from multiple neurotransmitter systems. We also found that anaesthetics and psychedelics/cognitive enhancers are largely opposite in terms of their association with neurotransmitters in the cortex – although not without exceptions. Remarkably, the effects of mind-altering drugs are topographically organised along multiple hierarchical gradients of brain function, anatomy, and neurobiology. Finally, we found that co-susceptibility to pharmacological perturbations recapitulates co-susceptibility to disorder-induced structural perturbations.

The diverse mapping between drug-induced functional reorganisation and neurotransmitters that we recovered (Figure 5) clearly shows the power of our multivariate approach to detect both expected and novel relationships between drugs and neurotransmitters. Many of the drugs considered here are known to have varied molecular targets, beyond the primary ones through which they exert their effects. The present results add another dimension to recent work employing a similar multivariate approach to relate gene expression of receptors with subjective reports

of psychedelic experiences, which also found widespread involvement of multiple receptors⁵³. In addition, the drugs we considered here have profound effects on the mind after a single acute dose¹⁴³, from cognitive enhancement to hallucinations to the suppression of consciousness altogether. Such far-reaching effects are accompanied by sometimes drastic repercussions on brain function and dynamics: it stands to reason that such widespread reorganisation would not leave many neurotransmitter pathways unaffected - even those that are not directly involved in generating the altered state in question.

The broadly opposite characterisation of traditional anaesthetics and most psychedelics is aligned with their respective effects on the complexity of brain activity and connectivity, which is reduced by GABA-ergic anaesthesia but increased by LSD, ayahuasca and psychedelic doses of ketamine, as well as other psychedelics^{18,21,23,62,144–154}. Similarly, psychedelics (including sub-anaesthetic ketamine) and anaesthetics were recently shown to exert opposite effects on structure-function coupling: whereas anaesthesia increases the dependence of brain activity on the underlying structural network, LSD, psilocybin, and sub-anaesthetic ketamine induce fMRI BOLD signals that are increasingly liberal with respect to the underlying structural network organisation²¹. Intriguingly, we found that anaesthetic doses of ketamine align more closely with psychedelic (sub-anaesthetic) doses of ketamine than with anaesthetics such as propofol and sevoflurane. Although the ketamine-anaesthetised volunteers were behaviourally unresponsive, as for the traditional anaesthetics, they subsequently reported a wide range of vivid hallucinatory experiences⁷⁵. Thus, as per ketamine's characterisation as a dissociative anaesthetic, in subjective terms their consciousness was not suppressed but rather profoundly altered in a manner more similar to psychedelics than anaesthetics. Therefore, the neurotransmitter signatures of the two levels of ketamine align with the molecular effects and subjective effects, rather than with the behavioural effects.

The main division we observed in terms of neurotransmitters is between receptors and transporters, which displayed opposite associations with drug-induced effects. Specifically pertaining to PLS1, we found that transporters covary with cognitive enhancers and most psychedelics in primary sensory and motor regions, whereas

receptors covary with GABA-ergic anaesthetics in transmodal association cortices. Hierarchical organisation of pharmacologically-induced functional reorganisation stands to reason based on prior evidence: both psychedelics and anaesthetics have been shown to have potent effects on the activity and connectivity of higher-order association cortices, and the default mode network in particular^{18,60,61,66,75,155–157}. In addition, serotonergic psychedelics also exert powerful influences on the visual cortex at the other end of the cortical hierarchy⁶⁰, and as a result they have been shown to induce a “flattening” of the principal gradient of functional connectivity¹⁵⁸.

Having established that the effects of mind-altering drugs are hierarchically organised, the question then becomes: why should mind-altering drugs exert their effects in such a hierarchically organised fashion? Multiple aspects of neuroanatomy may contribute to this effect. First, the principal component of variation of receptor expression is itself organised along the brain’s sensory-to-association hierarchical axis²⁷ - and so is, for instance, the distribution of the serotonin 2A receptor, the main direct target of serotonergic psychedelics³¹. Second, transmodal cortices are characterised by increased excitability¹⁵⁹ and a predominance of feedback efferent connections²⁷: combined with their high diversity of receptor expression across layers²⁷, these regions may be especially susceptible to receive and amplify multiple pharmacological influences.

Third, we observed that for the first latent variable, neurotransmitter and drug scores also correlate with the map of regional cerebral blood flow; since ultimately the bloodstream is how drugs reach their regional molecular targets, greater cerebral blood flow in transmodal cortices may facilitate especially high availability of the drug in these regions (although it should be noted that some drugs can also have effects on heart rate and neuro-vascular coupling). Finally, regions of transmodal cortex have high neuron and synapse density^{129,160} and tend to have numerous, far-reaching, and diversely distributed anatomical connections¹⁶¹, as well as the highest prevalence of synergistic (complementary) interactions with the rest of the brain¹²⁹, so that any effects that are exerted in these regions may quickly reverberate throughout the whole cortex.

To summarise, we conjecture that the hierarchical organisation of pharmacologically-induced changes in FC may be explained as follows: transmodal association cortices are especially diverse in their receptor profiles, and rich in some key receptors; in addition to being more susceptible to pharmacological intervention due to higher expression of receptors, blood flow is poised to bring greater amounts of drug to these very cortices; and once these cortices' activity is perturbed, the perturbation can reverberate widely, thanks to their widespread and diverse connectivity. Of course, the drugs we included were chosen precisely because of their powerful effects on cognition and subjective experience, so it stands to reason that their effects should align with the division between primary and higher-order cortices (which also aligns with the principal component of variation obtained from NeuroSynth term-based meta-analysis). In other words, drugs whose effects on functional connectivity are less selective for higher versus lower ends of the cortical hierarchy may simply be less likely to exert mind-altering effects of the kind that we chose to focus on in this work.

More broadly, we found that pairs of regions that are more similar in terms of their susceptibility to pharmacologically-induced FC changes, are also more similar in their susceptibility to cortical alterations associated with a variety of neuropsychiatric disorders. This observation suggests a broader pattern of both pharmacological (acute) and neuroanatomical (chronic) susceptibility across regions. We speculate that this joint susceptibility may be related to regional relevance for cognitive function: indeed, we found that this joint vulnerability can be understood in terms of two multimodal principal gradients of variation over the cortex: one of them resembling the principal gradient of functional connectivity (and principal latent variable of neurotransmitter-drug association), and the other anchored in dorsal prefrontal cortex at one end, and temporal cortex at the other. The association between disorder co-susceptibility and co-susceptibility to pharmacologically-induced functional reorganisation sheds new light on recent evidence that the principal gradient of neurotransmitter expression is particularly relevant for predicting a wide spectrum of disease-specific cortical morphology¹¹³, by showing that this observation extends to the effects of engaging different receptors. This interpretation is further supported by our own evidence that pharmacological perturbations are shaped by neurotransmitter co-expression.

613

614 The results reported here open new possibilities for data-driven, multivariate
615 mapping between the brain's high-dimensional neurotransmitter landscape and the
616 effects of potent pharmacological interventions on the brain's functional architecture.
617 Crucially, neuropsychiatric disorders and candidate pharmacological treatments for
618 them ultimately need to exert their effects on cognition and behaviour by influencing
619 brain function. In this light, it is intriguing that susceptibility to disorder-related cortical
620 abnormalities correlates with susceptibility to pharmacological intervention. This
621 observation suggests that regions that are structurally most vulnerable to disease
622 (which presumably in turn shapes their functional architecture) may also be the ones
623 that are most susceptible to re-balancing of their functional organisation by an
624 appropriate choice of pharmacological intervention. This work represents the
625 necessary first step towards identifying novel and perhaps unexpected associations
626 between drugs and neurotransmitters, as well as elucidating the known ones in a
627 data-driven manner.

628 Limitations and future directions

629 Although the main strength of our study is our extensive coverage of both
630 neurotransmitters and pharmacological data, it is important to acknowledge that
631 neither is complete: in particular, our sample did by no means exhaustively include
632 all mind-altering drugs that have been studied: prominent additions for future work
633 may include the psychedelic kappa opioid receptor agonist salvinorin-A¹⁶², the
634 sedative dexmedetomidine, an alpha-2 receptor agonist^{163–165} – but also alcohol or
635 caffeine, arguably the two most widely used psychoactive substances. We also
636 acknowledge that the pharmacological datasets included here come from limited
637 samples that have been studied before, and future replication in different datasets
638 with the same drugs (as we have done here for propofol) would also be desirable.

639

640 The datasets included here come from different sources and locations, and were
641 acquired under a variety of conditions. We endeavoured to mitigate scanner and
642 acquisition differences by re-preprocessing all data with the same pipeline, and
643 following uniform denoising procedures, rather than following the various pipelines
644 originally employed by each group. Further mitigation of the acquisition differences

between datasets should come from our within-subject design in healthy individuals (except for the methylphenidate dataset, which comes from TBI patients¹⁰; although we showed that our results remain qualitatively the same if this dataset is excluded; Fig. S6). Nevertheless, we cannot exclude some residual influence of such differences on our results (e.g., eyes open versus closed; the ayahuasca data were acquired at a lower field strength of 1.5T; the TRs varied from 1.671s for modafinil, to 3s for psilocybin). Similar considerations about the differences between datasets apply for the PET data, as discussed in detail in the original publication collecting the PET maps³¹. Likewise, the coverage of neurotransmitter receptors and transporters, though the most extensive available to date and obtained *in vivo* rather than post-mortem, is far from exhaustive. The same limitation also applies to the ENIGMA disorder data¹³⁰: many more disorders, diseases, and conditions exist than the ones considered here. And although the ENIGMA consortium provides datasets from large samples with standardised pipelines, ensuring robust results, the patient populations may exhibit co-morbidities and/or be undergoing treatment. In addition, the available maps do not directly reflect changes in tissue volume, but rather the effect size of patient-control statistical comparisons, in terms of only one low resolution cortical-only parcellation.

In addition to the inevitable limitations of analysing large-scale datasets from multiple sites, there are also limitations of our analytic framework. Although we report a macroscale spatial association between neurotransmitter expression and pharmacologically-induced functional reorganisation that is statistically unexpected based on autocorrelation alone, caution is warranted when drawing inferences from statistical results to the underlying biology. We used linear models that assume independence between observations – an assumption that mostly does not hold in the brain, given the possibility of nonlinear effects in how drugs exert their effects on the brain's intricately connected neurotransmitter systems. To mitigate this limitation, throughout this work we triangulated towards a robust statistical mapping between neurotransmitters and drugs by combining cross-validation and conservative null models that account for the spatial dependencies between regions⁵⁹.

Another limitation is that, due to data availability and well documented differences in PET radioligand uptake between cortical and subcortical structures^{31,166,167}, our work

was mainly restricted to the cortex, and we considered the subcortex separately. The thalamus, brainstem, and other subcortical structures are prominently involved in mediating cortico-cortical interactions and the effects of both psychedelics, anaesthetics, and cognitive enhancers^{16,18,51,66,163,168–173}. We expect that future work suitable data for whole-brain coverage (ideally including cerebellum and brainstem) may provide richer insights than the sum of their individual contributions.

More broadly, the other main limitation of this work is its correlational nature: receptors and drugs were mapped in separate cohorts of individuals, and identifying spatially correlated patterns does not guarantee the causal involvement of the neurotransmitters in question. Experimental interventions will be required to conclusively demonstrate causal involvement, and elucidate the underlying neurobiological pathways. However, we emphasise that our results generate empirically testable hypotheses about which neurotransmitters may be involved with the macroscale effects of different drugs on brain function. Such hypotheses may be tested experimentally, but also *in silico*: whole-brain computational modelling is becoming increasingly prominent as a tool to investigate the causal mechanisms that drive brain activity and organisation in healthy and pathological conditions^{174–177}. Crucially, the more biologically-inspired models (e.g. dynamic mean-field) can also be enriched with further information, such as regional myelination¹⁵⁹, or the regional distribution of specific receptors and ion channels obtained from PET or transcriptomics^{71–73,178,179}, to reflect neurotransmitter influences. This approach may complement experimental manipulations, making it possible to systematically evaluate the causal effects of combinations of different neuromodulators on the brain's functional connectivity.

Conclusion

Here, we mapped the functional chemoarchitecture of the human brain, by relating the regional changes in fMRI functional connectivity induced by 10 different mind-altering drugs, and the regional distribution of 19 neurotransmitter receptors and transporters obtained from PET. This work provides a computational framework to characterise how mind-altering pharmacological agents engage the brain's rich neurotransmitter landscape to exert their effects on brain function. Our analytic

workflow could find application across the breadth of human cognitive and clinical neuroscience, with the potential to shed light on alterations of neurotransmission underlying neuropsychiatric conditions, which are known to involve a combination of anatomical and neurochemical imbalances. More broadly, our framework could also find fruitful application for data-driven prediction of the effects of candidate drugs on the brain: the mapping between neurotransmitters and pharmacological effects on brain function offers an indispensable biological lens that can reveal neurotransmitter targets for therapeutic intervention. In summary, we demonstrate that diverse patterns of neurotransmitter expression are variously engaged by an array of potent pharmacological interventions, ultimately manifesting as a large-scale hierarchical axis. Collectively, these results highlight a statistical link between molecular dynamics and drug-induced reorganisation of functional architecture.

Materials and Methods

Description of datasets

Propofol

Propofol (2,6-diisopropylphenol) is perhaps the most common agent used for intravenous induction and maintenance of general anaesthesia³². One of the chief reasons for its widespread use, both in the operating room and for scientific studies, is propofol's rapid action, which allow for precise titration and therefore greater control over the induction and emergence process. Additionally, propofol has minimal effects on both regional cerebral blood flow¹⁸⁰, and the coupling between blood flow and metabolism¹⁸¹, thereby reducing the number of potential confounding effects. Propofol is a potent agonist of inhibitory GABA-A receptors, directly activating them as well as increasing their affinity for agonists^{33,34}, leading to suppressed neuronal activity. Propofol also blocks Na⁺ channels, inhibiting glutamate release¹⁸² and more broadly it inhibits neurotransmitter release at

presynaptic terminals¹⁸³. There is also some evidence that it may affect the dopaminergic system^{51,184,185}. Here, we included two independent propofol datasets.

Western University dataset: Recruitment

The Western University ("Western") propofol data were collected between May and November 2014 at the Robarts Research Institute, Western University, London, Ontario (Canada), and have been published before^{18,151,186,187}. The study received ethical approval from the Health Sciences Research Ethics Board and Psychology Research Ethics Board of Western University (Ontario, Canada). Healthy volunteers (n=19) were recruited (18–40 years; 13 males). Volunteers were right-handed, native English speakers, and had no history of neurological disorders. In accordance with relevant ethical guidelines, each volunteer provided written informed consent, and received monetary compensation for their time. Due to equipment malfunction or physiological impediments to anaesthesia in the scanner, data from n=3 participants (1 male) were excluded from analyses, leaving a total n=16 for analysis¹⁸.

Western University dataset: Study protocol

Resting-state fMRI data were acquired at different propofol levels: no sedation (Awake), Deep anaesthesia (corresponding to Ramsay score of 5) and also during post-anaesthetic recovery. As previously reported¹⁸, for each condition fMRI acquisition began after two anaesthesiologists and one anaesthesia nurse independently assessed Ramsay level in the scanning room. The anaesthesiologists and the anaesthesia nurse could not be blinded to experimental condition, since part of their role involved determining the participants' level of anaesthesia. Note that the Ramsay score is designed for critical care patients, and therefore participants did not receive a score during the Awake condition before propofol administration: rather, they were required to be fully awake, alert and communicating appropriately. To provide a further, independent evaluation of participants' level of responsiveness, they were asked to perform two tasks: a test of verbal memory recall, and a computer-based auditory target-detection task. Wakefulness was also monitored using an infrared camera placed inside the scanner.

Propofol was administered intravenously using an AS50 auto syringe infusion pump (Baxter Healthcare, Singapore); an effect-site/plasma steering algorithm combined with the computer-controlled infusion pump was used to achieve step-wise sedation increments, followed by manual adjustments as required to reach the desired target concentrations of propofol according to the TIVA Trainer (European Society for Intravenous Anaesthesia, european-society-for-intravenous-anaesthesia.eu) pharmacokinetic simulation program. This software also specified the blood concentrations of propofol, following the Marsh 3-compartment model, which were used as targets for the pharmacokinetic model providing target-controlled infusion. After an initial propofol target effect-site concentration of $0.6 \mu\text{g mL}^{-1}$, concentration was gradually increased by increments of $0.3 \mu\text{g mL}^{-1}$, and Ramsay score was assessed after each increment: a further increment occurred if the Ramsay score was lower than 5. The mean estimated effect-site and plasma propofol concentrations were kept stable by the pharmacokinetic model delivered via the TIVA Trainer infusion pump. Ramsay level 5 was achieved when participants stopped responding to verbal commands, were unable to engage in conversation, and were rousable only to physical stimulation. Once both anaesthesiologists and the anaesthesia nurse all agreed that Ramsay sedation level 5 had been reached, and participants stopped responding to both tasks, data acquisition was initiated. The mean estimated effect-site propofol concentration was $2.48 (1.82- 3.14) \mu\text{g mL}^{-1}$, and the mean estimated plasma propofol concentration was $2.68 (1.92- 3.44) \mu\text{g mL}^{-1}$. Mean total mass of propofol administered was $486.58 (373.30- 599.86) \text{ mg}$. These values of variability are typical for the pharmacokinetics and pharmacodynamics of propofol. Oxygen was titrated to maintain SpO₂ above 96%.

At Ramsay 5 level, participants remained capable of spontaneous cardiovascular function and ventilation. However, the sedation procedure did not take place in a hospital setting; therefore, intubation during scanning could not be used to ensure airway security during scanning. Consequently, although two anaesthesiologists closely monitored each participant, scanner time was minimised to ensure return to normal breathing following deep sedation. No state changes or movement were noted during the deep sedation scanning for any of the participants included in the study¹⁸. Propofol was discontinued following the deep anaesthesia scan, and participants reached level 2 of the Ramsey scale approximately 11 minutes

afterwards, as indicated by clear and rapid responses to verbal commands. This corresponds to the “recovery” period.

As previously reported¹⁸, once in the scanner participants were instructed to relax with closed eyes, without falling asleep. Resting-state functional MRI in the absence of any tasks was acquired for 8 minutes for each participant. A further scan was also acquired during auditory presentation of a plot-driven story through headphones (5-minute long). Participants were instructed to listen while keeping their eyes closed. The present analysis focuses on the resting-state data only; the story scan data have been published separately¹⁸⁸ and will not be discussed further here.

Western University dataset: MRI Data Acquisition

As previously reported¹⁸, MRI scanning was performed using a 3-Tesla Siemens Tim Trio scanner (32-channel coil), and 256 functional volumes (echo-planar images, EPI) were collected from each participant, with the following parameters: slices = 33, with 25% inter-slice gap; resolution = 3mm isotropic; TR = 2000ms; TE = 30ms; flip angle = 75 degrees; matrix size = 64x64. The order of acquisition was interleaved, bottom-up. Anatomical scanning was also performed, acquiring a high-resolution T1-weighted volume (32-channel coil, 1mm isotropic voxel size) with a 3D MPRAGE sequence, using the following parameters: TA = 5min, TE = 4.25ms, 240x256 matrix size, 9 degrees flip angle¹⁸.

Cambridge University dataset: Recruitment

The Cambridge University (“Cambridge”) propofol dataset is described in detail in a previous publication⁶⁷. Sixteen healthy volunteer subjects were initially recruited for scanning. In addition to the original 16 volunteers, data were acquired for nine additional participants using the same procedures, bringing the total number of participants in this dataset to 25 (11 males, 14 females; mean age 34.7 years, SD = 9.0 years). Ethical approval for these studies was obtained from the Cambridgeshire 2 Regional Ethics Committee, and all subjects gave informed consent to participate in the study. Volunteers were informed of the risks of propofol administration, such as loss of consciousness, respiratory and cardiovascular depression. They were also informed about more minor effects of propofol such as pain on injection, sedation

and amnesia. In addition, standard information about intravenous cannulation, blood sampling and MRI scanning was provided.

Cambridge University dataset: Study protocol

Three target plasma levels of propofol were used - no drug (Awake), 0.6 mg/ml (Mild sedation) and 1.2 mg/ml (Moderate sedation). Scanning (rs-fMRI) was acquired at each stage, and also at Recovery; anatomical images were also acquired. The level of sedation was assessed verbally immediately before and after each of the scanning runs. Propofol was administered intravenously as a “target controlled infusion” (plasma concentration mode), using an Alaris PK infusion pump (Carefusion, Basingstoke, UK). A period of 10 min was allowed for equilibration of plasma and effect-site propofol concentrations. Blood samples were drawn towards the end of each titration period and before the plasma target was altered, to assess plasma propofol levels. In total, 6 blood samples were drawn during the study. The mean (SD) measured plasma propofol concentration was 304.8 (141.1) ng/ml during mild sedation, 723.3 (320.5) ng/ml during moderate sedation and 275.8 (75.42) ng/ml during recovery. Mean (SD) total mass of propofol administered was 210.15 (33.17) mg, equivalent to 3.0 (0.47) mg/kg. Two senior anaesthetists were present during scanning sessions and observed the subjects throughout the study from the MRI control room and on a video link that showed the subject in the scanner. Electrocardiography and pulse oximetry were performed continuously, and measurements of heart rate, non-invasive blood pressure, and oxygen saturation were recorded at regular intervals.

Cambridge University dataset: MRI Data Acquisition

The acquisition procedures are described in detail in the original study³⁷. Briefly, MRI data were acquired on a Siemens Trio 3T scanner (WBIC, Cambridge). For each level of sedation, 150 rs-fMRI volumes (5 min scanning) were acquired. Each functional BOLD volume consisted of 32 interleaved, descending, oblique axial slices, 3 mm thick with interslice gap of 0.75 mm and in-plane resolution of 3 mm,

field of view = 192x192 mm, repetition time = 2000 ms, acquisition time = 2 s, time echo = 30 ms, and flip angle 78. T1-weighted structural images at 1 mm isotropic resolution were also acquired in the sagittal plane, using an MPRAGE sequence with TR = 2250 ms, TI = 900 ms, TE = 2.99 ms and flip angle = 9 degrees, for localization purposes. During scanning, volunteers were instructed to close their eyes and think about nothing in particular throughout the acquisition of the resting state BOLD data. Of the 25 healthy subjects, 15 were ultimately retained (7 males, 8 females): 10 were excluded, either because of missing scans (n=2), or due of excessive motion in the scanner (n=8, 5mm maximum motion threshold). For the analyses presented in this paper, we only considered the Awake, Moderate (i.e., loss of behavioural responsiveness) and Recovery resting-state scans.

Sevoflurane

Sevoflurane is an inhalational anaesthetic: specifically, a halogenated ether. Although its exact molecular mechanisms of action are yet to be fully elucidated, in vivo and in vitro evidence indicates that it acts primarily via GABA-A receptors^{2,35–38}, but also interacts with NMDA, AMPA^{39,189,190} and nicotinic ACh receptors^{191,192}. Additionally, electrophysiologic investigation suggests possible affinity for as well as Na⁺, K⁺ and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels¹⁹³.

Sevoflurane dataset: Recruitment

The data included here have been published before^{66,194–196}, and we refer the reader to the original publication for details⁶⁶. The ethics committee of the medical school of the Technische Universität München (München, Germany) approved the current study, which was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from volunteers at least 48 h before the study session. Twenty healthy adult men (20 to 36 years of age; mean, 26 years) were recruited through campus notices and personal contact, and compensated for their participation in the study.

Before inclusion in the study, detailed information was provided about the protocol and risks, and medical history was reviewed to assess any previous neurologic or psychiatric disorder. A focused physical examination was performed, and a resting electrocardiogram was recorded. Further exclusion criteria were the following: physical status other than American Society of Anesthesiologists physical status I, chronic intake of medication or drugs, hardness of hearing or deafness, absence of fluency in German, known or suspected disposition to malignant hyperthermia, acute hepatic porphyria, history of halothane hepatitis, obesity with a body mass index more than 30 kg/m², gastrointestinal disorders with a disposition for gastroesophageal regurgitation, known or suspected difficult airway, and presence of metal implants. Data acquisition took place between June and December 2013.

Sevoflurane dataset: Study protocol

Sevoflurane concentrations were chosen so that subjects tolerated artificial ventilation (reached at 2.0 vol%) and that burst-suppression (BS) was reached in all participants (around 4.4 vol%). To make group comparisons feasible, an intermediate concentration of 3.0 vol% was also used. In the MRI scanner, volunteers were in a resting state with eyes closed for 700s. Since EEG data were simultaneously acquired during MRI scanning⁶⁶ (though they are not analysed in the present study), visual online inspection of the EEG was used to verify that participants did not fall asleep during the pre-anaesthesia baseline scan. Sevoflurane mixed with oxygen was administered via a tight-fitting facemask using an fMRI-compatible anaesthesia machine (Fabius Tiro, Dräger, Germany). Standard American Society of Anesthesiologists monitoring was performed: concentrations of sevoflurane, oxygen and carbon dioxide, were monitored using a cardiorespiratory monitor (DatexaS/3, General electric, USA). After administering an end-tidal sevoflurane concentration (etSev) of 0.4 vol% for 5 min, sevoflurane concentration was increased in a stepwise fashion by 0.2 vol% every 3 min until the participant became unconscious, as judged by the loss of responsiveness (LOR) to the repeatedly spoken command “squeeze my hand” two consecutive times. Sevoflurane concentration was then increased to reach an end-tidal concentration of approximately 3 vol%. When clinically indicated, ventilation was managed by the

physician and a laryngeal mask suitable for fMRI (I-gel, Intersurgical, United Kingdom) was inserted. The fraction of inspired oxygen was then set at 0.8, and mechanical ventilation was adjusted to maintain end-tidal carbon dioxide at steady concentrations of 33 ± 1.71 mmHg during BS, 34 ± 1.12 mmHg during 3 vol%, and 33 ± 1.49 mmHg during 2 vol% (throughout this article, mean $\pm$ SD). Norepinephrine was given by continuous infusion ($0.1 \pm 0.01 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) through an intravenous catheter in a vein on the dorsum of the hand, to maintain the mean arterial blood pressure close to baseline values (baseline, 96 ± 9.36 mmHg; BS, 88 ± 7.55 mmHg; 3 vol%, 88 ± 8.4 mmHg; 2 vol%, 89 ± 9.37 mmHg; follow-up, 98 ± 9.41 mmHg). After insertion of the laryngeal mask airway, sevoflurane concentration was gradually increased until the EEG showed burst-suppression with suppression periods of at least 1,000 ms and about 50% suppression of electrical activity (reached at 4.34 ± 0.22 vol%), which is characteristic of deep anaesthesia. At that point, another 700s of electroencephalogram and fMRI was recorded. Further 700s of data were acquired at steady end-tidal sevoflurane concentrations of 3 and 2 vol%, respectively, each after an equilibration time of 15 min. In a final step, etSev was reduced to two times the concentration at LOR. However, most of the subjects moved or did not tolerate the laryngeal mask any more under this condition: therefore, this stage was not included in the analysis⁶⁶.

Sevoflurane administration was then terminated, and the scanner table was slid out of the MRI scanner to monitor post-anaesthetic recovery. The volunteer was manually ventilated until spontaneous ventilation returned. The laryngeal mask was removed as soon as the patient opened his mouth on command. The physician regularly asked the volunteer to squeeze their hand: recovery of responsiveness was noted to occur as soon as the command was followed. Fifteen minutes after the time of recovery of responsiveness, the Brice interview was administered to assess for awareness during sevoflurane exposure; the interview was repeated on the phone the next day. After a total of 45 min of recovery time, another resting-state combined fMRI-EEG scan was acquired (with eyes closed, as for the baseline scan). When participants were alert, oriented, cooperative, and physiologically stable, they were taken home by a family member or a friend appointed in advance.

Sevoflurane dataset: MRI Data Acquisition

Although the original study acquired both functional MRI (fMRI) and electroencephalographic (EEG) data, in the present work we only considered the fMRI data. Data acquisition was carried out on a 3-Tesla magnetic resonance imaging scanner (Achieva Quasar Dual 3.0T 16CH, The Netherlands) with an eight-channel, phased-array head coil. The data were collected using a gradient echo planar imaging sequence (echo time = 30 ms, repetition time (TR) = 1.838 s, flip angle = 75°, field of view = 220 × 220 mm², matrix = 72 × 72, 32 slices, slice thickness = 3 mm, and 1 mm interslice gap; 700-s acquisition time, resulting in 350 functional volumes). The anatomical scan was acquired before the functional scan using a T1-weighted MPRAGE sequence with 240 × 240 × 170 voxels (1×1×1 mm voxel size) covering the whole brain. A total of 16 volunteers completed the full protocol and were included in our analyses; one subject was excluded due to high motion, leaving N=15 for analysis. Here, we used fMRI data from the Awake, 3% vol, and Recovery scans.

Ketamine

Ketamine is a multi-faceted drug, in terms of both neurophysiology and how it affects subjective experience. Depending on dosage, it can act as a “dissociative” anaesthetic (high dose)^{22,24,75,76} or as an “atypical psychedelic” (at sub-anaesthetic dose)^{40–44}. At small doses, it has also found recent use as a fast-acting antidepressant^{197,198}. Both the anaesthetic and psychedelic effects of ketamine are in some respect unusual; unlike widely used anaesthetics like propofol and sevoflurane, ketamine does not exert its anaesthetic function through agonism of GABA receptors, nor does it recruit sleep-promoting hypothalamic nuclei, which it appears to suppress instead^{24,43}. Likewise, although ketamine does induce psychedelic-like symptoms such as perceptual distortions, vivid imagery and hallucinations, like classic psychedelics, it also induces prominent dissociative symptoms of disembodiment^{43,64,199–201}. Its psychedelic action is not mediated by the serotonin 2A receptor, on which classic psychedelics operate^{46,49}; although its precise mechanisms of action are yet to be fully elucidated, ketamine appears to be

primarily an antagonist of NMDA and HCN1 receptors; however, evidence suggests that cholinergic, aminergic, and opioid systems may also play modulatory roles^{44,45,50}.

Anaesthetic ketamine dataset: Recruitment

The anaesthetic ketamine data used here have been published before ⁷⁵, and we refer the reader to the original publication for details. The original study was approved by approval by the ethics committee of the Medical school of the university of Liege (University Hospital, Liege, Belgium), registered at eudract 2010-023016-13. 14 right-handed volunteers were recruited via advertisements in an Internet forum (5 women; median age [range], 25 [19 to 31] years). Each participant provided written informed consent to participation, and underwent medical interview and physical examination before their participation.

Anaesthetic ketamine dataset: Study protocol

The volunteers were requested to fast for at least 6 h from solids and 2 h from liquids before the experimental session. After structural MR image acquisition, subjects were removed from the MRI scanner, and 64 electroencephalogram (EEG) scalp electrodes were placed to allow for simultaneous EEG-fMRI. Here, we only focus on the functional MRI data.

An 18-gauge intravenous catheter (BD Insyte-W; Becton Dickinson Infusion Therapy Systems inc., USA) was then placed into a vein of the left forearm and infused using normal saline at a rate of 20 ml/h. The intravenous line served for ketamine infusion and eventual administration of rescue medications. a 20-gauge arterial catheter (Arrow International Inc., USA) was also placed into the left radial artery, under strict sterile conditions and after performing local anesthesia with 3 ml of 1% lidocaine. This catheter was equipped with a monitoring set (TruWave, Edwards Lifesciences, Dominican Republic) and served for arterial blood sampling and gas analysis. standard MRI compatible anaesthesia monitoring (Magnitude 3150M; Invivo Research, inc., USA) was also placed to allow continuous monitoring and recording of the electrocardiogram, heart rate, blood pressure, pulse oxymetry (spO₂), and

breathing frequency throughout the scanning and recovery periods. Through a loosely fitting plastic facemask, additional oxygen at a rate of 5 l/min was provided to volunteers, whose breathing always remained spontaneous. One certified anaesthesiologist and one neurologist were present throughout the experiment. After setting all needed equipment and monitoring, the volunteers were comfortably installed in the MRI tray. The most comfortable supine position attainable was sought to avoid painful stimulation related to position. all volunteers wore earplugs to attenuate noise and earphones to allow communication with investigators; one investigator remained in the MRI scan room at all times.

Ketamine was administered using a computer-controlled intravenous infusion device composed of a separate laptop computer. A 50-ml syringe was filled with normal saline containing racemic ketamine (Ketalar, Pfizer Ltd., Turkey) at a concentration of 10mg/ml. The pharmacokinetic model used to drive the pump was the domino model, which has been demonstrated to have acceptable predictive performance. This system commands infusion pump rates to allow targeting precise effect-site and plasma concentrations of ketamine, based on several biometric parameters. For each change in ketamine concentration, a 5-min equilibration period was allowed after reaching the target, to permit equilibration of ketamine concentration between body compartments. The depth of sedation was assessed using the Ramsay Scale and the University of Michigan Sedation Scale. Each evaluation took place immediately before and after each fMRI data acquisition sequence. Volunteers were asked to strongly squeeze the hand of the investigator, and the command was repeated twice. For that purpose, and for close watch of the volunteer, an investigator continuously stayed inside the MRI room.

A first fMRI data acquisition was performed in the absence of any infusion of ketamine. Ketamine infusion was then started, and its target concentration was increased by steps of 0.5 µg/ml until a level of sedation corresponding to RS 3 to 4 or UMSS 1 to 2 was reached (light sedation, S1). After the 5-min equilibration period, a novel sequence of data acquisition occurred, consisting of the same sequence of events as during W1. Ketamine target concentration was then further increased by steps of 0.5 µg/ml until RS 5 to 6 or UMSS 4 (deep sedation [s2]), and the same sequence of data acquisition was again performed. Because ketamine has a long

elimination half-life and to limit time spent in the fMRI scanner for the volunteer, the temporal order of those clinical states was not randomized. For the same reason, a recovery experimental condition could not be achieved. After those acquisitions, the infusion of ketamine was stopped, and the subject was removed from the fMRI scanner to allow for comfortable recovery. The presence of dreaming during ketamine infusion was checked through a phone call at distance from the experimental session. Here, we only consider the awake and deep sedation scans.

Anaesthetic ketamine dataset: MRI Data Acquisition

MRI data were acquired on a 3T Siemens Allegra scanner (Siemens AG, Germany; Echo Planar Imaging sequence using 32 slices; repetition time = 2,460 ms; echo time = 40 ms; field of view = 220 mm; voxel size = $3.45 \times 3.45 \times 3$ mm; and matrix size = $64 \times 64 \times 32$). A high-resolution structural T1 image was acquired in each volunteer at the beginning of the whole experiment for coregistration to the functional data.

A total of 6 participants had to be excluded from the study and further data analysis because of excessive agitation and movements (5 subjects) or voluntary withdrawal (1 subject), leaving 8 for analysis⁷⁵.

Psychedelic ketamine dataset: Recruitment

The sub-anaesthetic (“psychedelic”) ketamine data included in this study have been published before⁶⁴, and we refer the reader to the original publication for details. Briefly, a total of 21 participants (10 males; mean age 28.7 years, SD = 3.2 years) were recruited via advertisements placed throughout central Cambridge, UK⁶⁴. All participants underwent a screening interview in which they were asked whether they had previously been diagnosed or treated for any mental health problems and whether they had ever taken any psychotropic medications. Participants reporting a personal history of any mental health problems or a history of any treatment were excluded from the study. All participants were right-handed, were free of current of previous psychiatric or neurological disorder or substance abuse problems, and had

no history of cardiovascular illness or family history of psychiatric disorder/substance abuse. The study was approved by the Cambridge Local Research and Ethics Committee, and all participants provided written informed consent in accordance with ethics committee guidelines.

Psychedelic ketamine dataset: Study protocol

Participants were scanned (resting-state functional MRI and anatomical T1) on two occasions, separated by at least 1 week. On one occasion, they received a continuous computer-controlled intravenous infusion of a racemic ketamine solution (2 mg/ml) until a targeted plasma concentration of 100 ng/ml was reached. This concentration was sustained throughout the protocol. A saline infusion was administered on the other occasion. Infusion order was randomly counterbalanced across participants. The infusion was performed and monitored by a trained anaesthetist (R.A.) who was unblinded for safety reasons, but who otherwise had minimal contact with participants. At all other times, participants were supervised by investigators blinded to the infusion protocol. The participants remained blinded until both assessments were completed. Bilateral intravenous catheters were inserted into volunteers' forearms, one for infusion, and the other for serial blood sampling. A validated and previously implemented²⁰² three-compartment pharmacokinetic model was used to achieve a constant plasma concentration of 100 ng/ml using a computerized pump (Graseby 3500, Graseby Medical, UK). The infusion continued for 15 min to allow stabilization of plasma levels. Blood samples were drawn before and after the resting fMRI scan and then placed on ice. Plasma was obtained by centrifugation and stored at -70 °C. Plasma ketamine concentrations were measured by gas chromatography–mass spectrometry.

Psychedelic ketamine dataset: MRI Data Acquisition

All MRI and assessment procedures were identical across assessment occasions. Scanning was performed using a 3.0 T MRI scanner (Siemens Magnetom, Trio Tim, Erlangen, Germany) equipped with a 12-channel array coil located at the Wolfson

Brain Imaging Centre, Addenbrooke's Hospital, Cambridge, UK. T2*-weighted echo-planar images were acquired under eyes-closed resting-state conditions. Participants were instructed to close their eyes and let the minds wander without going to sleep. Subsequent participant debriefing ensured that no participants fell asleep during the scan. Imaging parameters were: 3x3x3.75mm voxel size, with a time-to-repetition (TR) of 2000 ms, time-to-echo (TE) of 30 ms, flip angle of 78° in 64x64 matrix size, and 240mm field of view (FOV). A total of 300 volumes comprising 32 slices each were obtained. In addition, high-resolution anatomical T1 images were acquired using a three-dimensional magnetic-prepared rapid gradient echo (MPPRAGE) sequence. In all, 176 contiguous sagittal slices of 1.0mm thickness using a TR of 2300 ms, TE of 2.98 ms, flip angle of 91°, and a FOV of 256mm in 240x256 matrix were acquired with a voxel size of 1.0mm³. One participant was excluded due to excessive movement, resulting in a final sample of N=20 subjects.

LSD

LSD (lysergic acid diethylamide) is perhaps the best-known among classic psychedelics, inducing a powerful state of altered consciousness with subjective experiences including hallucinations and “ego dissolution”^{46,48,49}. Substantial work in humans and animals has demonstrated that LSD influences neuromodulation, having affinity for multiple receptors, primarily serotonergic (5-HT_{2A}, 5-HT_{1A/B}, 5-HT₆, 5-HT₇) and dopaminergic (D₁ and D₂ receptors)^{46,48,52,203,204}.

The main neural and subjective effects of LSD originate from its agonism of the 5-HT_{2A} receptor: both effects are abolished by pre-treatment with the non-selective 5HT₂ antagonist ketanserin, which has highest affinity for the 5HT_{2A} receptor^{171,205}. In humans, functional connectivity under LSD shows significant correspondence with the spatial distribution of the 5HT_{2A} receptor²⁰⁶. Providing evidence for a mechanistic role, both PET maps and transcriptomic maps of the 5HT_{2A} receptor (but not other serotonin receptors) have been shown to improve the ability of computational models to recapitulate the effects of LSD on brain activity and connectivity, as measured by fMRI^{72,73,178}. Therefore, pharmacological and in silico

evidence converge towards the central role of the 5HT2A receptor for LSD's ability to alter consciousness and its neural underpinnings – although other receptors have also been shown to play an auxiliary role⁵².

LSD dataset: Recruitment

The LSD data employed here have been extensively published, and we refer to the original publication for details⁶⁰. Briefly, collection of these data⁶⁰ was approved by the National Research Ethics Service Committee London–West London and was conducted in accordance with the revised declaration of Helsinki (2000), the International Committee on Harmonization Good Clinical Practice guidelines and National Health Service Research Governance Framework. Imperial College London sponsored the research, which was conducted under a Home Office license for research with schedule 1 drugs. All participants were recruited via word of mouth and provided written informed consent to participate after study briefing and screening for physical and mental health. The screening for physical health included electrocardiogram (ECG), routine blood tests, and urine test for recent drug use and pregnancy. A psychiatric interview was conducted and participants provided full disclosure of their drug use history. Key exclusion criteria included: < 21 years of age, personal history of diagnosed psychiatric illness, immediate family history of a psychotic disorder, an absence of previous experience with a classic psychedelic drug (e.g. LSD, mescaline, psilocybin/magic mushrooms or DMT/ayahuasca), any psychedelic drug use within 6 weeks of the first scanning day, pregnancy, problematic alcohol use (i.e. > 40 units consumed per week), or a medically significant condition rendering the volunteer unsuitable for the study. Twenty healthy volunteers with previous experience using psychedelic drugs were scanned.

LSD dataset: Study protocol

Volunteers underwent two scans, 14 days apart. On one day they were given a placebo (10-mL saline) and the other they were given an active dose of LSD (75 µg of LSD in 10-mL saline). The order of the conditions was balanced across

participants, and participants were blind to this order but the researchers were not. Participants carried out VAS-style ratings via button-press and a digital display screen presented after each scan, and the 11-factor altered states of consciousness (ASC) questionnaire was completed at the end of each dosing day⁶⁰. All participants reported marked alterations of consciousness under LSD.

The data acquisition protocols were described in detail in the original publication ⁶⁰, so we will only describe them in brief here. The infusion (drug/placebo) was administered over 2 min and occurred 115 min before the resting-state scans were initiated. After infusion, subjects had a brief acclimation period in a mock MRI scanner to prepare them for the experience of being in the real machine. ASL and BOLD scanning consisted of three seven-minute eyes closed resting state scans. The ASL data were not analysed for this study, and will not be discussed further.

LSD dataset: MRI Data Acquisition

The first and third scans were eyes-closed, resting state without stimulation, while the second scan involved listening to music; however, this scan was not used in this analysis. The precise length of each of the two BOLD scans included here was 7:20 minutes. For the present analysis, these two scans were concatenated together in time. Imaging was performed on a 3T GE HDx system. High-resolution anatomical images were acquired with 3D fast spoiled gradient echo scans in an axial orientation, with field of view = 256x256x192 and matrix = 256x256x129 to yield 1mm isotropic voxel resolution. TR/TE = 7.9/3.0ms; inversion time = 450ms; flip angle = 20. BOLD-weighted fMRI data were acquired using a gradient echo planer imaging sequence, TR/TE = 2000/35ms, FoV = 220mm, 64x64 acquisition matrix, parallel acceleration factor = 2, 90 flip angle. Thirty five oblique axial slices were acquired in an interleaved fashion, each 3.4mm thick with zero slice gap (3.4mm isotropic voxels). One subject aborted the experiment due to anxiety and four others were excluded for excessive motion (measured in terms of frame-wise displacement), leaving 15 subjects for analysis (11 males, 4 females; mean age 30.5 years, SD = 8.0 years)⁶⁰.

1205 Psilocybin

1206 Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), a prodrug of psilocin (4-OH-
1207 N,N-dimethyltryptamine), is a classic psychedelic, the active compound of “magic
1208 mushrooms” of the *Psilocybe* family. Although its psychedelic effects are exerted via
1209 agonism of the serotonin 2A receptor^{16,207–210}, psilocin also has demonstrated affinity
1210 for additional receptors, in particular serotonin 1A and 2C receptors²¹¹.

1211

1212 Psilocybin dataset: Recruitment

1213 Data acquisition for this dataset is described in detail previously⁶¹, and will only be
1214 summarised here. Volunteers were at least 21 years of age, with no personal or
1215 family history of a major psychiatric disorder, no substance dependence, no
1216 cardiovascular disease, and no history of adverse response to a psychedelic drug
1217 yielded datasets for nine participants. All subjects had used psilocybin at least once
1218 before, but not within 6 weeks of the study. The study was approved by a National
1219 Health Service research ethics committee and all participants gave informed consent
1220 to participate in the study.

1221

1222 Psilocybin dataset: Study protocol

1223 In brief, fifteen health volunteers underwent two MRI scanning sessions at least 14
1224 days apart. In each session, subjects were injected with either psilocybin (2 mg
1225 dissolved in 10 mL of saline, 60-s intravenous injection) or a placebo (10 mL of
1226 saline, 60-s i.v. injection) in a counterbalanced design. The infusions began exactly 6
1227 min after the start of the 12-min fMRI scans and lasted 60s. The subjective effects of
1228 psilocybin were felt almost immediately after injection and sustained for the
1229 remainder of the scanning session. At the end of each session, subjects were asked
1230 to rate the overall intensity of their subjective experience under the drug (or placebo)
1231 and to comment on their wakefulness level throughout the scan. As expected, all
1232 participants rated the subjective effects of psilocybin (mean intensity = 6.9/10 ± 2.6)
1233 as much stronger than placebo (mean intensity = 0.4/10 ± 0.6) and none of the

1234 subjects reported falling asleep during either scanning session. The 5 minutes of
1235 post-infusion data were used for the present analysis.

1236

1237 Psilocybin dataset: MRI Data Acquisition

1238 Neuroimaging data were acquired using a 3T GE HDx MRI system. Anatomical
1239 scans were performed before each functional scan and thus prior to administering
1240 either the drug or placebo. Structural scans were collected using a 3D fast spoiled
1241 gradient echo scans in an axial orientation, with field of view = $256 \times 256 \times 192$ and
1242 matrix = $256 \times 256 \times 192$ to yield 1 mm isotropic voxel resolution (repetition time/echo
1243 time TR/TE = 7.9/3.0 ms; inversion time = 450 ms; flip angle = 20). BOLD-weighted
1244 fMRI data were acquired at 3T using a gradient echo EPI sequence, TR/TE 3000/35
1245 ms, field-of-view = 192 mm, 64×64 acquisition matrix, parallel acceleration factor =
1246 2, 90° flip angle. Fifty-three oblique axial slices were acquired in an interleaved
1247 fashion, each 3 mm thick with zero slice gap ($3 \times 3 \times 3$ -mm voxels). Following the
1248 same exclusion criteria for motion described above for the LSD dataset, N=9
1249 subjects were kept for analysis (seven men; age, 32 ± 8.9 SD years of age).

1250

1251 DMT

1252 The tryptamine N,N-di-methyltryptamine (DMT) is a fast-acting mind-altering drug,
1253 capable of inducing an immersive state of altered consciousness, with vivid and
1254 detailed visual hallucinations. It is found endogenously in trace amounts in the
1255 human body^{46,212,213}, but it is orally inert and therefore primarily studied as
1256 intravenous injection, whereupon its effects have very rapid onset (2-5 minutes) and
1257 offset, effectively fading within 30 minutes of administration^{214–217}. Pharmacologically,
1258 DMT binds to sigma-1 and serotonin (particularly 2A and 2C) receptors, but also
1259 dopamine D1 and alpha-adrenergic receptors^{218–221}.

1260

1261 DMT dataset: Recruitment

The original DMT study (Timmermann *et al.*, under review) was approved by the National Research Ethics (NRES) Committee London – Brent and the Health Research Authority and was conducted under the guidelines of the revised Declaration of Helsinki (2000), the International Committee on Harmonisation Good Clinical Practices guidelines, and the National Health Service Research Governance Framework. Imperial College London sponsored the research, which was conducted under a Home Office license for research with Schedule 1 drugs. An initial visit was focused on assessing physical and mental health to ensure suitability, and participants provided written informed consent. In total, 20 participants completed all study visits (7 female, mean age = 33.5 years, SD = 7.9).

DMT dataset: Study protocol

This was a single-blind, placebo-controlled, counter-balanced design. Volunteers participated in two testing days, 2 weeks apart. On each testing day, volunteers (after testing for drugs of abuse) were involved in 2 separate scanning sessions. In this initial session (task-free) they received intravenous (IV) administration of either placebo (saline) or DMT (in fumarate form) in a counter-balanced order (half of the participants received placebo and the other half received DMT). This first session always consisted of continuous resting-state scans which lasted 28 minutes with DMT/placebo administered at the end of the 8th minute and scanning was over 20 minutes after injection. Participants lay in the scanner with their eyes closed (an eye mask was used to prevent eyes-opening). Following the scanning procedure, participants were interviewed and completed questionnaires designed to assess the subjective effects experienced during the scan. Here, we focused on the 8 minutes post-infusion, corresponding to peak DMT experience.

DMT dataset: MRI Data Acquisition

MR images were acquired in a 3T MR scanner (Siemens Magnetom Verio syngo MR B17) using a 12-channel head coil for compatibility with EEG acquisition. Functional imaging was performed using a T2*-weighted BOLD sensitive gradient echo planar imaging sequence (repetition time (TR) = 2000ms, echo time (TE) = 30ms,

acquisition time (TA) = 28.06 mins, flip angle (FA) = 80°, voxel size = 3.0 x 3.0 x 3.0mm³, 35 slices, interslice distance = 0mm. Whole-brain T1-weighted structural images were also acquired. EEG was also acquired, but here we only focus on the fMRI data. Seven out of 20 participants were discarded from analyses due to excessive movement, or only completing one session, leaving 13 subjects for analysis.

Ayahuasca

The Amazonian beverage ayahuasca is typically used in shamanic religious rituals, where it is obtained as a tea made from two plants: *Psychotria viridis* and *Banisteriopsis caapi*. *Psychotria viridis* contains DMT, which binds to sigma-1 and serotonin (particularly 2A) receptors^{218,219}. *Banisteriopsis caapi* contains beta-carboline alkaloids, notably harmine, tetrahydroharmine (THH), and harmaline. As potent monoamine oxidase inhibitors (MAOI), harmine and harmaline prevent the degradation of DMT by liver MAO that would otherwise render it orally inert; additionally, they also increase levels of monoamine neurotransmitters; and THH acts as a mild selective serotonin reuptake inhibitor and a weak MAOI^{222–224}. As for other classic psychedelics, engagement of the 5-HT_{2A} receptor appears to be a necessary condition for the brain and subjective effects of ayahuasca to manifest²²⁵.

Ayahuasca dataset: Recruitment

The ayahuasca data that we used have been published before^{62,144}, and we refer the reader to the original publication for details. Briefly, data were obtained from 9 healthy right-handed adult volunteers (mean age 31.3, from 24 to 47 years), all who were experienced users of Ayahuasca with at least 5 years use (twice a month) and at least 8 years of formal education. The experimental procedure was approved by the Ethics and Research Committee of the University of São Paulo at Ribeirão Preto (process number 14672/2006). Written informed consent was obtained from all volunteers, who belonged to the Santo Daime religious organisation. All experimental procedures were performed in accordance with the relevant guidelines

and regulations. Volunteers were not under medication for at least 3 months prior to the scanning session and were abstinent from caffeine, nicotine and alcohol prior to the acquisition. They had no history of neurological or psychiatric disorders, as assessed by DSM-IV structured interview⁷¹. Subjects ingested 120–200 mL (2.2 mL/kg of body weight) of Ayahuasca known to contain 0.8 mg/mL of DMT and 0.21 mg/mL of harmine. Harmaline was not detected via the chromatography analysis, at the threshold of 0.02 mg/mL⁷.

Ayahuasca dataset: Study protocol

Volunteers underwent two distinct fMRI scanning sessions: (i) before and (ii) 40 minutes after Ayahuasca intake, when the subjective effects become noticeable (the volunteers drank 2.2 mL/kg of body weight and the Ayahuasca contained 0.8 mg/mL of DMT and 0.21 mg/mL of harmine). In both cases, participants were instructed to close their eyes and remain awake and at rest, without performing any task.

Ayahuasca dataset: MRI Data Acquisition

The fMRI images were obtained in a 1.5 T scanner (Siemens, Magnetom Vision), using an EPI-BOLD like sequence comprising 150 volumes, with the following parameters: TR = 1700 ms; TE = 66 ms; FOV = 220 mm; matrix 64 × 64; voxel dimensions of 1.72 mm × 1.72 mm × 1.72 mm. Whole brain high resolution T1-weighted images were also acquired (156 contiguous sagittal slices) using a multiplanar reconstructed gradient-echo sequence, with the following parameters: TR = 9.7 ms; TE = 44 ms; flip angle 12°; matrix 256 × 256; FOV = 256 mm, voxel size = 1 mm × 1 mm × 1 mm. Data from one volunteer were excluded from analyses due to acquisition limitations resulting in incomplete brain coverage. The final dataset included 8 subjects.

1351 MDMA

1352 3,4-methylenedioxymethamphetamine (MDMA) combines the subjective effects of a
1353 stimulant and a psychedelic, inducing powerful euphoria and prosociality, but also
1354 mild visual hallucinations^{226–228}. It inhibits reuptake of noradrenaline, dopamine, and
1355 serotonin by acting on their respective transporters, and it also stimulates their
1356 release – with preferential effects on 5-HT mediating at least in part its induction of
1357 positive mood^{226–228}.

1358

1359 MDMA dataset: Recruitment

1360 The MDMA dataset has been published before^{63,229}, and we refer the reader to the
1361 original publications for details. The study was approved by the National Research
1362 Ethics Service West London Research Ethics Committee, Joint Compliance and
1363 Research Office of Imperial College London, Research Ethics Committee of Imperial
1364 College London, Head of the Department of Medicine of Imperial College London,
1365 Imanova Centre for Imaging Science, and Faculty of Medicine of Imperial College
1366 London. The study was conducted in accordance with Good Clinical Practice
1367 guidelines. A Home Office Licence was obtained for the storage and handling of a
1368 Schedule 1 drug. Imperial College London sponsored the research.

1369

1370 The study included 25 healthy participants (mean age, 34±11 years; 7 females) with
1371 at least one previous experience with MDMA. None of the participants had used
1372 MDMA for at least 7 days or other drugs for at least 48 hours, which was confirmed
1373 by a urine screen. An alcohol breathalyzer test confirmed that none of the
1374 participants had recently consumed alcohol. Volunteers were screened for good
1375 physical and mental health, and magnetic resonance imaging compatibility. All
1376 subjects were deemed physically and mentally healthy, and none had any history of
1377 drug or alcohol dependence or diagnosed psychiatric disorder.

1378

1379 MDMA dataset: Study protocol

1380 The study design was within-subjects, and placebo-controlled. Participants were
1381 scanned twice, once after MDMA (100 mg encapsulated MDMA-HCl) and once after
1382 placebo (encapsulated ascorbic acid/vitamin-C), in a double-blind, randomized,

counterbalanced order. The MDMA and placebo study days were separated by 7 days, and on each occasion, participants underwent two arterial spin labelling (ASL; not included in the present analysis) and two resting-state BOLD fMRI scans within a 90-minute scan session. Biochip Array Technology (Radox Laboratories Ltd., Co., Antrim, United Kingdom) was used to detect MDMA from plasma samples obtained shortly after each participant's MDMA scanning session (i.e., 2 hours after capsule ingestion).

The first resting-state BOLD scan took place 60 minutes after capsule ingestion and the second resting-state BOLD scan occurred 113 minutes after capsule ingestion. Participants relaxed with their eyes closed during the ASL and BOLD resting state scans. Peak subjective effects were reported ~100 minutes post administration of MDMA, consistent with the plasma t-max of MDMA. Therefore, here we focus on the second MDMA and placebo rs-fMRI scans.

MDMA dataset: MRI Data Acquisition

MR images were acquired on a 3T Siemens Tim Trio (Siemens Healthcare, Erlangen, Germany) using a 32-channel phased array head coil. Anatomical reference images were acquired using the ADNI-GO recommended MPRAGE parameters (1 mm isotropic voxels, TR = 2300 ms, TE = 2.98 ms, 160 sagittal slices, 256 x 256 in-plane resolution, flip angle = 9 degrees, bandwidth = 240 Hz/pixel, GRAPPA acceleration = 2). T2*-weighted echo-planar images (EPI) were acquired for the resting state BOLD functional scan using 3 mm isotropic voxels in a 192 mm in-plane FOV, TR = 2 s, echo time = 31 ms, 80 degree flip angle, 36 axial slices in each TR, bandwidth = 2298 Hz/pixel, and a GRAPPA acceleration of 2. Each rs-fMRI scan lasted for 6 minutes, corresponding to 180 functional volumes.

Modafinil

Modafinil is a wakefulness promoting drug used for the treatment of sleep disorders such as narcolepsy (under the commercial name Provigil), as well as finding use as a cognitive enhancer for attention and memory^{6,7,65}, and to combat the cognitive symptoms of Attention Deficit/Hyperactivity Disorder (ADHD), and mood disorders,

owing to its lower addiction risk in comparison with amphetamine-like psychostimulants^{6–9,230}. This drug has a broad neurotransmitter profile: it acts as a blocker of the dopamine and noradrenaline transporters, as well as modulating locus coeruleus noradrenergic firing, and acting on the wake-promoting hypothalamic neuropeptide orexin to activate the histamine system; it also influences both the glutamate and GABA systems^{8,231–235}.

Modafinil dataset: Recruitment

The modafinil dataset has been published before^{65,236}. As reported in the original publication, the study was approved by the ethics committee of University of Chieti (PROT 2008/09 COET on 14/10/2009) and conducted in accordance with the Helsinki Declaration. The study design was explained in detail and written informed consent was obtained from all participants involved in our study. Recruitment was performed throughout February 2011, drug/placebo administration and fMRI acquisitions started on March 2011, went on until January 2012, and the study was completed with the last fMRI session in January 2012. After securing financial coverage for costs related to the analysis of the study, the trial was registered on 10/09/2012 (NCT01684306<http://clinicaltrials.gov/ct2/show/NCT01684306>). After obtaining registration, the double-blind study was opened and analyzed.

This dataset was obtained from the OpenfMRI database. Its accession number is ds000133. A total of twenty six young male right-handed (as assessed by the Edinburgh Handedness inventory) adults (age range: 25–35 years) with comparable levels of education (13 years) were enrolled. All subjects had no past or current signs of psychiatric, neurological or medical (hypertension, cardiac disorders, epilepsy) conditions as determined by the Millon test and by clinical examination. Subjects showing visual or motor impairments were excluded as well as individuals taking psychoactive drugs or having a history of alcohol abuse. All volunteers were instructed to maintain their usual amount of nicotine and caffeine intake and avoid alcohol consumption in the 12h before the initiation of the study.

1445 Modafinil dataset: Study protocol

1446 Study subjects received, in a double blind fashion, either a single dose of modafinil
 1447 (100 mg) (modafinil group; N=13) or a placebo (placebo group; N=13) pill identical to
 1448 the drug. Randomization of study subjects was obtained by means of a random
 1449 number generator. Here, we only considered data from the modafinil group. The day
 1450 after drug/placebo assumption, subjects were asked about perceived side effects
 1451 and, in particular, sleep disturbances. All but one reported no modafinil-induced side-
 1452 effects or alterations in the sleep-wake cycle. Rs-fMRI BOLD data were separated in
 1453 three runs lasting four minutes each followed by high resolution T1 anatomical
 1454 images. Two scanning sessions took place: one before ingesting the drug/placebo,
 1455 and one 3 hours later, to account for pharmacokinetics. Subjects were asked to relax
 1456 while fixating the central point in the middle of a grey-background screen that was
 1457 projected on an LCD screen and viewed through a mirror placed above the subject's
 1458 head. Subject head was positioned within an eight-channel coil and foam padding
 1459 was employed to minimize involuntary head movements.

1460

1461 Modafinil dataset: MRI Data Acquisition

1462 BOLD functional imaging was performed with a Philips Achieva 3T Scanner (Philips
 1463 Medical Systems, Best, The Netherlands), using T2*-weighted echo planar imaging
 1464 (EPI) free induction decay (FID) sequences and applying the following parameters:
 1465 TE 35 ms, matrix size 64x64, FOV 256 mm, in-plane voxel size 464 mm, flip angle
 1466 75 degrees, slice thickness 4 mm and no gaps. 140 functional volumes consisting of
 1467 30 transaxial slices were acquired per run with a volume TR of 1,671 ms. High-
 1468 resolution structural images were acquired at the end of the three rs-fMRI runs
 1469 through a 3D MPRAGE sequence employing the following parameters: sagittal,
 1470 matrix 256x256, FOV 256 mm, slice thickness 1 mm, no gaps, in-plane voxel size 1
 1471 mm x 1 mm, flip angle 12 degrees, TR = 9.7 ms and TE = 4 ms. Two subjects from
 1472 the modafinil group were excluded from analysis due to acquisition limitations,
 1473 leaving N=11 subjects for analysis.

1474

1475 Methylphenidate

1476 Methylphenidate is used as a cognitive enhancer to treat the cognitive symptoms of
1477 ADHD and narcolepsy (under the name Ritalin)^{4,11}. Pharmacologically, it inhibits the
1478 reuptake of both dopamine and noradrenaline by blocking their transporters;
1479 although yet to be conclusively confirmed, there is also in vitro evidence suggesting
1480 an additional minor affinity of methylphenidate for the 5-HT_{1A} receptor^{237–243}.

1481

1482 Methylphenidate dataset: Recruitment

1483 The methylphenidate dataset used here has been published before^{10,51}. Unlike the
1484 other datasets included in this study, the methylphenidate data were not obtained
1485 from healthy controls, but rather from a cohort of patients suffering from traumatic
1486 brain injury (TBI). Volunteers with a history of moderate to severe traumatic brain
1487 injury (inclusion criteria: age 18–60 years and not recruited to more than three
1488 research studies within the calendar year) were referred from the Addenbrooke's
1489 Neurosciences Critical Care Unit Follow-Up Clinic, Addenbrooke's Traumatic Brain
1490 Injury Clinic and The Royal London Hospital Intensive Care Unit (see the original
1491 publication for details of patient injuries). The patients were sent a written invitation
1492 to take part in the study. All volunteers gave written informed consent before
1493 participating in the study.

1494 Thirty-eight volunteers were recruited to the study; 17 (12 male, 5 female) into the
1495 TBI arm of the study and 21 (13 male, 8 female) into the healthy control (HC) arm of
1496 the study. Exclusion criteria included National Adult Reading Test (NART) <70, Mini
1497 Mental State Examination (MMSE) <23, left-handedness, history of drug/alcohol
1498 abuse, history of psychiatric or neurological disorders, contraindications for MRI
1499 scanning, medication that may affect cognitive performance or prescribed for
1500 depression, and any physical handicap that could prevent the completion of testing.

1501 Our sample contains mostly patients with diffuse axonal injuries and small lesions.
1502 The patients were at least 6 months post TBI. Four sustained moderate TBI with a
1503 score of between 9 and 12 on the Glasgow Coma Scale (GCS) and 11 sustained

severe TBI with a GCS score of 8 or below on presentation. The mean age of the patient group was 36 years (± 13 years).

Methylphenidate dataset: Study protocol

The study consisted of two visits (separated by 2–4 weeks) for both groups of participants. The TBI volunteers were randomly allocated in a Latin square design to receive one of the two interventions on the first visit (a placebo tablet or 30 mg tablet of methylphenidate), and the alternate intervention on the second visit. The decision to use 30 mg of methylphenidate was based on comparable doses used in previous studies in healthy participants, as well as NICE guidelines for medication in adults (www.nice.org.uk) which stipulate that when methylphenidate is titrated for side effects and responsiveness in each individual subject, the dose should range from a minimum of 15 mg to a maximum dose of 100 mg. As the dose of methylphenidate was not calculated by the participant's body weight, an interventional dose at the lower end of the dose range was chosen. After a delay of 75 min to ensure that peak plasma levels of methylphenidate were reached, the volunteers completed an MRI scan which included both fMRI and structural image acquisition. The healthy controls attended their two fMRI assessments at the same time interval as the patients, but without any pharmacological intervention. Therefore, here we only considered the patient data.

Methylphenidate dataset: MRI Data Acquisition

MRI data were acquired on a Siemens Trio 3-Tesla MR system (Siemens AG, Munich, Germany). MRI scanning started with the acquisition of a localizer scan and was followed by a 3D high resolution MPRAGE image [TR 2,300 ms, Echo Time (TE) 2.98 ms, Flip Angle 9°, FOV 256×256 mm²]. Diffusion Tensor Imaging (DTI) data (63 non-collinear directions, $b=1,000$ s/mm² with one volume acquired without diffusion weighting ($b=0$), echo time 106 ms, repetition time 1,700 ms, field of view 192×192 mm, 2 mm isotropic voxels) were also collected to investigate white matter integrity. Here, we did not analyse the DTI data.

Functional imaging data were acquired using an echo-planar imaging (EPI) sequence with parameters TR = 2,000 ms, TE = 30 ms, Flip Angle = 78°, FOV 192×192 mm², in-plane resolution 3.0×3.0 mm, 32 slices 3.0 mm thick with a gap of 0.75 mm between slices. Two patients were excluded from the analysis (one patient only attended one of the study sessions and the other had excessive movement artifacts in their fMRI scan), leaving N=15 patients for analysis.

Functional MRI preprocessing and denoising

Preprocessing

To maximise the uniformity between the different datasets included here, we elected to preprocess all datasets using the same pipeline, as opposed to relying on the different pipelines originally employed by the group that collected each dataset. For the same reason, we also applied the same denoising procedure across all datasets.

For each dataset and condition, we applied a standard preprocessing pipeline, which we have previously employed with pharmaco-MRI datasets comprising both anaesthetics and psychedelics^{18,21,145,196}, demonstrating its suitability for the present analysis. Preprocessing was performed using the CONN toolbox, version 17f (CONN; <http://www.nitrc.org/projects/conn>)²⁴⁴ based on Statistical Parametric Mapping 12 (<http://www.fil.ion.ucl.ac.uk/spm>), implemented in MATLAB 2016a. The pipeline involved the following steps: removal of the first 10s, to achieve steady-state magnetization; motion correction; slice-timing correction; identification of outlier volumes for subsequent scrubbing by means of the quality assurance/artifact rejection software *art* (http://www.nitrc.org/projects/artifact_detect); normalisation to Montreal Neurological Institute (MNI-152) standard space (2 mm isotropic resampling resolution), using the segmented grey matter image from each volunteer's T1-weighted anatomical image, together with an *a priori* grey matter template.

Denoising

Denoising was also performed using the CONN toolbox, using the same approach as in our previous publications with pharmaco-MRI datasets^{18,21,145,196}, which has also been adopted with similar pharmaco-MRI datasets in publications by independent groups²⁴⁵.

Pharmacological agents can induce alterations in physiological parameters (heart rate, breathing rate, motion) or neurovascular coupling²⁴⁶. The anatomical CompCor (aCompCor) method removes physiological fluctuations by extracting principal components from regions unlikely to be modulated by neural activity; these components are then included as nuisance regressors²⁴⁷. Following this approach, five principal components were extracted from white matter and cerebrospinal fluid signals (using individual tissue masks obtained from the T1-weighted structural MRI images)²⁴⁵; and regressed out from the functional data together with six subject-specific realignment parameters (three translations and three rotations) as well as their first-order temporal derivatives; followed by scrubbing of outliers identified by ART, using Ordinary Least Squares regression²⁴⁴. Finally, the denoised BOLD signal timeseries were linearly detrended and band-pass filtered to eliminate both low-frequency drift effects and high-frequency noise, thus retaining frequencies between 0.008 and 0.09 Hz.

The step of global signal regression (GSR) has received substantial attention in the literature as a denoising method^{248–250}. GSR mathematically mandates that approximately 50% of correlations between regions will be negative²⁵¹; however, the proportion of anticorrelations between brain regions has been shown to vary across states of consciousness, including anaesthesia and psychedelics^{18,145}. Furthermore, recent work has demonstrated that the global signal contains information about states of consciousness, across pharmacological and pathological perturbations²⁵². Therefore, in line with ours and others' previous studies, here we avoided GSR in favour of the aCompCor denoising procedure, which is among those recommended²⁴⁹.

Summarising pharmacological effects on brain function

For each subject at each condition, the denoised regional BOLD signals were parcellated into 100 cortical regions according to the local-global functional

parcellation of Schaefer and colleagues¹¹². The parcellated regional BOLD signals were then correlated (“functional connectivity”); after removing negative-valued edges, the regional strength of functional connectivity (node strength) was measured for each region. The regional change in FC strength was then quantified for each subject (for the methylphenidate dataset, this was quantified with respect to the mean of controls’ node strength values). Finally, for each dataset, we computed the mean across subjects of the FC strength deltas. Therefore, each pharmacological intervention was summarised as one vector of regional FC strength deltas (Figure 1).

Receptor maps from Positron Emission Tomography

Receptor densities were estimated using PET tracer studies for a total of 19 receptors and transporters, across 9 neurotransmitter systems, recently made available by Hansen and colleagues at https://github.com/netneurolab/hansen_receptors³¹. These include dopamine (D1⁷⁷, D2^{78–81}, DAT⁸²), norepinephrine (NET^{83–86}), serotonin (5-HT1A⁸⁷, 5-HT1B^{87–90,90–92}, 5-HT2A⁹³, 5-HT4⁹³, 5-HT6^{94,95}, 5-HTT⁹³), acetylcholine ($\alpha 4\beta 2$ ^{96,97}, M1⁹⁸, VACHT^{99,100}), glutamate (mGluR5^{101,102}, NMDA^{103,104}), GABA (GABA-A¹⁰⁵), histamine (H3¹⁰⁶), cannabinoid (CB1^{107–110}), and opioid (MOR¹¹¹). Volumetric PET images were registered to the MNI-ICBM 152 nonlinear 2009 (version c, asymmetric) template, averaged across participants within each study, then parcellated and receptors/transporters with more than one mean image of the same tracer (5-HT1b, D2, VACHT) were combined using a weighted average. See the dedicated article by Hansen *et al.*³¹ for detailed information about each PET dataset and their respective acquisition and limitations.

Partial Least Squares Analysis

PLS analysis (implemented using MATLAB code from Hansen *et al.*, 2021)⁵⁹ available at https://github.com/netneurolab/hansen_genescognition/tree/master/PLS) was used to relate regional neurotransmitter density to pharmacologically-induced functional connectivity changes. PLS analysis is an unsupervised multivariate statistical technique that decomposes relationships between two datasets (in our

case, neurotransmitter density with n regions and r neurotransmitters, $X_{n \times r}$, and drug-induced functional connectivity changes, $Y_{n \times d}$ with n regions and d drugs) into orthogonal sets of latent variables with maximum covariance, which are linear combinations of the original data^{119,120}. In other words, PLS finds components from the predictor variables (100×19 matrix of regional neurotransmitter receptor and transporter density scores) that have maximum covariance with the response variables (100×15 matrix of regional changes in FC induced by different drugs). The PLS components (i.e., linear combinations of the weighted neurotransmitter density) are ranked by covariance between predictor and response variables, so that the first few PLS components provide a low-dimensional representation of the covariance between the higher dimensional data matrices. Thus, the first PLS component (PLS1) is the linear combination of the weighted neurotransmitter density scores that have a brain expression map that covaries the most with the map of regional FC changes.

This is achieved by z-scoring both data matrices column-wise and applying singular value decomposition on the matrix $Y'X$, such that:

$$(Y'X)' = USV' \quad (1)$$

where $U_{g \times t}$ and $V_{t \times t}$ are orthonormal matrices consisting of left and right singular vectors and $S_{t \times t}$ is a diagonal matrix of singular values. The i^{th} columns of U and V constitute a latent variable, and the i^{th} singular value in S represents the covariance between singular vectors. The i^{th} singular value is proportional to the amount of covariance between neurotransmitter density, and drug-induced FC changes captured by the i^{th} latent variable, where the effect size can be estimated as the ratio of the squared singular value to the sum of all squared singular values. In the present study, the left singular vectors (that is, the columns of U) represent the degree to which each neurotransmitter contributes to the latent variable and demonstrate the extracted association between neurotransmitter density and drug-induced FC changes (neurotransmitter weights). The right singular vectors (that is, the columns of V) represent the degree to which the FC changes contribute to the same latent variable (term weights). Positively weighed neurotransmitters covary

with positively weighed drug-induced changes, and negatively weighed neurotransmitters covary with negatively weighed drug-induced changes.

Scores at each brain region for each latent variable can be computed by projecting the original data onto the singular vector weights. Positively scored brain regions are regions that demonstrate the covariance between the prevalence of positively weighted neurotransmitters and positively weighted drug-induced effects (and vice versa for negatively scored brain regions). Loadings for each variable were computed as the Pearson's correlation between each individual variable's activity (neurotransmitter density and drug-induced FC changes) and the PLS analysis-derived neurotransmitter score pattern. Squaring the loading (a correlation) equals the percentage variance shared between an original variable and the PLS analysis-derived latent variable. Variables with high absolute loadings are highly correlated to the score pattern, indicating a large amount of shared variance between the individual variable and the latent variable. We confirmed that PLS1 explained the largest amount of variance by testing across a range of PLS components (between 1 and 12) and quantifying the relative variance explained by each component.

Hierarchical organisation

We quantified the spatial similarity of each pharmacologically-induced pattern of change in FC strength, with several canonical maps of hierarchical brain organisation ("canonical brain hierarchies") derived from multimodal neuroimaging. We considered the anatomical gradient of intracortical myelination obtained from T1w/T2w MRI ratio⁵⁸; evolutionary cortical expansion obtained by comparing human and macaque¹²⁶; the principal component of variation in gene expression from the Allen Human Brain Atlas transcriptomic database (AHBA; <https://human.brain-map.org/>), referred to as "AHBA PC1"^{54,59,127}; the principal component of variation in task activation from NeuroSynth, (<https://github.com/neurosynth/neurosynth>), an online meta-analytic tool that synthesizes results from more than 15,000 published fMRI studies by searching for high-frequency key words that are published alongside fMRI voxel coordinates, using the volumetric association test maps (referred to as

“NeuroSynth PC1”)^{54,59,128}; the map of cerebral blood flow⁵⁴; the principal gradient of variation in functional connectivity⁵⁷; and a recently derived gradient of regional prevalence of different kinds of information, from redundancy to synergy¹²⁹.

ENIGMA cortical vulnerability data

Patterns of cortical thickness were collected for the available 11 neurological, neurodevelopmental, and psychiatric disorders from the ENIGMA (Enhancing Neuroimaging Genetics through Meta-Analysis) consortium and the *enigma* toolbox (<https://github.com/MICA-MNI/ENIGMA>)¹³⁰: 22q11.2 deletion syndrome¹³¹, attention-deficit/hyperactivity disorder¹³², autism spectrum disorder¹³³, idiopathic generalized epilepsy¹³⁴, right temporal lobe epilepsy¹³⁴, left temporal lobe epilepsy¹³⁴, depression¹³⁵, obsessive-compulsive disorder¹³⁶, schizophrenia¹³⁷, bipolar disorder¹³⁸, and Parkinson’s disease¹³⁹. The ENIGMA consortium is a data-sharing initiative that relies on standardized image acquisition and processing pipelines, such that disorder maps are comparable²⁵³. Altogether, over 21,000 patients were scanned across the thirteen disorders, against almost 26,000 controls. The values for each map are z-scored effect sizes (Cohen’s *d*) of cortical thickness in patient populations versus healthy controls. Imaging and processing protocols can be found at <http://enigma.ini.usc.edu/protocols/>.

For every brain region, we constructed an 11-element vector of disorder abnormality, where each element represents a disorder’s cortical abnormality at the region. For every pair of brain regions, we correlated the abnormality vectors to quantify how similarly two brain regions are affected across disorders. This results in a region-by-region matrix of “disorder co-susceptibility”¹¹³.

Gradients from diffusion map embedding

We used the *BrainSpace* toolbox¹⁴⁰ (<http://brainspace.readthedocs.io>) to obtain gradients from diffusion map embedding. A joint network of disease- and drug- co-susceptibility was obtained from the network fusion procedure of Paquola *et al*

(2020)¹⁴¹, through horizontal concatenation of matrices and production of a node-to-node affinity matrix using row-wise normalised angle similarity.

We then employed diffusion map embedding, a nonlinear manifold learning technique based on the graph Laplacian^{140,254}, to obtain a low dimensional representation of the joint drug- and disorder-susceptibility. A single parameter α controls the influence of the sampling density on the manifold ($\alpha = 0$, maximal influence; $\alpha = 1$, no influence). Following extensive previous work using this approach with neuroimaging data^{57,140,141,255}, we set $\alpha = 0.5$, to retain the global relations between data points in the embedded space. The ability to combine global and local geometry differentiates diffusion maps from global-only methods, such as PCA and multidimensional scaling¹⁴¹. A small number of components can be identified based on decreasing eigenvalues. The decay of each eigenvector obtained from the diffusion map embedding provides an overall measure of the connectivity between nodes along the axis delineated by its spatial distribution on the brain (gradient).

Statistical Analysis

The statistical significance of the variance explained by each PLS model was tested by permuting the response variables 1,000 times, while considering the spatial dependency of the data by using spatial autocorrelation-preserving permutation tests, termed spin tests^{121–124}. Parcel coordinates were projected onto the spherical surface and then randomly rotated and original parcels were reassigned the value of the closest rotated parcel (10,000 repetitions). The procedure was performed at the parcel resolution rather than the vertex resolution to avoid upsampling the data. In PLS analysis, the spin test is applied to the singular values (or equivalently, the covariance explained) of the latent variables, producing a null distribution of singular values. This is done applying PLS analysis to the original X matrix and a spun Y matrix. The spin test embodies the null hypothesis that neurotransmitter density and drug-induced FC changes are spatially correlated with each other only because of inherent spatial autocorrelation. The p-value is computed as the proportion of null singular values that are greater in magnitude than the empirical singular values. Thus, these p-values represent the probability that the observed spatial

correspondence between neurotransmitter density and drug-induced FC changes could occur by randomly correlating maps with comparable spatial autocorrelation. Likewise, spatial similarity between brain maps was quantified in terms of Spearman correlation, and statistical significance was assessed against a spin-based null model with preserved spatial autocorrelation, as described above^{121–124}.

Data and code availability

Pharmacological-fMRI data are available upon request from the corresponding authors of the original publications referenced herein. The neurotransmitter receptor and transporter PET maps are available at https://github.com/netneurolab/hansen_receptors. The Allen Human Brain Atlas transcriptomic database is available at <https://human.brain-map.org/>; NeuroSynth is available at <https://github.com/neurosynth/neurosynth>. The ENIGMA toolbox and data are available at <https://github.com/MICA-MNI/ENIGMA>. MATLAB code for Partial Least Squares analysis is freely available at https://github.com/netneurolab/hansen_genescognition/tree/master/PLS.

Acknowledgements

This work was carried out thanks to support from the Gates Cambridge Trust (OPP 1144) [to AIL]; the Wellcome Trust Research Training Fellowship (grant no. 083660/Z/07/Z), Raymond and Beverly Sackler Studentship, and the Cambridge Commonwealth Trust [to RA]; the Canadian Institute for Advanced Research (CIFAR; grant RCZB/072 RG93193) [to DKM and EAS]; the Cambridge Biomedical Research Centre and NIHR Senior Investigator Awards and the British Oxygen Professorship of the Royal College of Anaesthetists [to DKM]; the Stephen Erskine Fellowship at Queens' College, Cambridge [to EAS]. BM is supported by the Natural Sciences and Engineering Research Council of Canada (NSERC Discovery Grant RGPIN #017-04265) and Canada Research Chairs Program. JYH is supported by the Helmholtz International BigBrain Analytics & Learning Laboratory, the Natural Sciences and Engineering Research Council of Canada, and Fonds de recherches de Québec. AMO is supported by the Canada Excellence Research Chairs program (215063); LN acknowledges support by the L'Oreal-Unesco for Women in Science Excellence Research Fellowship. LR acknowledges support of the Imperial College President's Scholarship. PC and NLNA are supported by the Belgian National Funds for Scientific Research (F.R.S-FNRS). PC is also

supported by the GIGA-Doctoral School for Health Sciences (University of Liège). NLNA also acknowledges the support of the Human Brain Project. SLS is supported by funds from the Italian Department of Education [Fondo per gli Investimenti della Ricerca di Base (FIRB) 2003; Programmi di Ricerca di Rilevante Interesse nazionale (PRIN) 2008]. RLC-H was supported by the Alex Mosley Charitable Trust and supporters of the Centre for Psychedelic Research during the period of data collection and now holds the Ralph Metzner Distinguished Professorship at UCSF. The original LSD study received support from a Crowd Funding Campaign and the Beckley Foundation, as part of the Beckley-Imperial Research Programme. The MDMA research was supported by funds provided by the British public service broadcast station Channel 4 and was performed as part of the Beckley Foundation–Imperial College research program. The DMT study was funded via a donation by Patrick Vernon. The Beckley Foundation mediated Patrick Vernon’s support. The psilocybin study received support from the Beckley Foundation and financial support from the Neuropsychanalysis Foundation, Multidisciplinary Association for Psychedelic Studies, and the Heffter Research Institute. The Cambridge ketamine study was funded by the Bernard Wolfe Health Neuroscience Fund and the Wellcome Trust. Data acquisition for the sevoflurane dataset was funded by the Departments of Anesthesiology, Neurology, and Neuroradiology of the Klinikum rechts der Isar of the Technical University Munich. The anaesthetic ketamine study was supported by the Belgian Society of Anesthesiology, Resuscitation, Perioperative medicine and Pain management (BeSARPP, Brussels, Belgium), the Belgian National Funds for Scientific Research (Brussels, Belgium), the European Commission (Brussels, Belgium), the James McDonnell Foundation (Saint Louis, Missouri), the European Space Agency (Brussels, Belgium), the Mind Science Foundation (San Antonio, Texas), the French Speaking Community Concerted Research Action (ARC - 06/11 – 340, Brussels, Belgium), the Public Utility Foundation “Université Européenne du Travail” (Brussels, Belgium), “Fondazione Europea di Ricerca Biomedica” (Milan, Italy), and the University and University Hospital of Liege (Liege, Belgium). This work was performed using resources provided by the Cambridge Service for Data Driven Discovery (CSD3) operated by the University of Cambridge Research Computing Service (www.csd3.cam.ac.uk), provided by Dell EMC and Intel using Tier-2 funding from the Engineering and Physical Sciences Research Council (capital grant EP/T022159/1), and DiRAC funding from the Science and Technology Facilities Council (www.dirac.ac.uk). Computing infrastructure at the Wolfson Brain Imaging Centre (WBIC-HPHI) was funded by the MRC research infrastructure award (MR/M009041/1). We acknowledge the contribution of Santo Daime members for volunteering and for providing the Ayahuasca. We also thank members of the Cognition and Consciousness Imaging Group, and of the Network Neuroscience Lab, for many helpful discussions.

1826

1827 Conflicts of Interest

1828 RCH reports receiving scientific advisory fees in the last 2 years from: Enttheon Biomedical and
1829 Beckley Psytech. D.B.A. serves as scientific advisor of Biomind Labs. VB has had financial
1830 relationships with the following companies: Orion Pharma, Medtronic, Edwards, and Elsevier. All
1831 other authors report no conflicts of interest.
1832

1833 Author Contributions

1834 AIL, JYH, EAS, BM conceived the study. AIL, JYH, EAS, BM designed the methodology and
1835 the analysis. AIL analysed the data. JYH, ARDP contributed to data analysis. RA, DKM,
1836 EAS, LR, RLCH, CT, DG, AR, RI, DJ, VB, AV, AD, OJ, MAB, NLNA, PC, AEM, DBdA, SLS,
1837 AMO, LN were involved in design, execution, and data acquisition and curation for the
1838 original studies for which the present data were collected. AIL, EAS, BM wrote the
1839 manuscript with feedback from co-authors.
1840

1841 References

- 1842
- 1843 1. Wandschneider, B. & Koepp, M. J. PharmacofMRI: Determining the functional
- 1844 anatomy of the effects of medication. *NeuroImage Clin.* **12**, 691–697 (2016).
- 1845 2. Brown, E. N., Lydic, R. & Schiff, N. D. General Anesthesia, Sleep, and Coma. *N. Engl.*
- 1846 *J. Med.* **27**, 2638–50 (2010).
- 1847 3. Cortese, S. *et al.* Comparative efficacy and tolerability of medications for attention-
- 1848 deficit hyperactivity disorder in children, adolescents, and adults: a systematic review
- 1849 and network meta-analysis. *Lancet Psychiatry* **5**, 727–738 (2018).
- 1850 4. Faraone, S. V. The pharmacology of amphetamine and methylphenidate: Relevance to
- 1851 the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric
- 1852 comorbidities. *Neurosci. Biobehav. Rev.* **87**, 255–270 (2018).
- 1853 5. Moldofsky, H., Broughton, R. J. & Hill, J. D. A randomized trial of the long-term,
- 1854 continued efficacy and safety of modafinil in narcolepsy. *Sleep Med.* **1**, 109–116
- 1855 (2000).
- 1856 6. Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J. & Sahakian, B. J.
- 1857 Cognitive enhancing effects of modafinil in healthy volunteers. *Psychopharmacology*
- 1858 *(Berl.)* **165**, 260–269 (2003).
- 1859 7. Minzenberg, M. J. & Carter, C. S. Modafinil: a review of neurochemical actions and
- 1860 effects on cognition. *Neuropsychopharmacol. Off. Publ. Am. Coll.*
- 1861 *Neuropsychopharmacol.* **33**, 1477–1502 (2008).
- 1862 8. Minzenberg, M. J., Watrous, A. J., Yoon, J. H., Ursu, S. & Carter, C. S. Modafinil shifts
- 1863 human locus coeruleus to low-tonic, high-phasic activity during functional MRI. *Science*
- 1864 **322**, 1700–1702 (2008).
- 1865 9. Kahbazi, M., Ghoreishi, A., Rahiminejad, F., Mohammadi, M.-R., Kamalipour, A. &
- 1866 Akhondzadeh, S. A randomized, double-blind and placebo-controlled trial of modafinil

- 1867 in children and adolescents with attention deficit and hyperactivity disorder. *Psychiatry*
1868 *Res.* **168**, 234–237 (2009).
- 1869 10. Manktelow, A. E., Menon, D. K., Sahakian, B. J. & Stamatakis, E. A. Working Memory
1870 after Traumatic Brain Injury: The Neural Basis of Improved Performance with
1871 Methylphenidate. *Front. Behav. Neurosci.* **11**, (2017).
- 1872 11. Storebø, O. J. *et al.* Methylphenidate for attention deficit hyperactivity disorder (ADHD)
1873 in children and adolescents – assessment of adverse events in non-randomised
1874 studies. *Cochrane Database Syst. Rev.* **2018**, CD012069 (2018).
- 1875 12. Carhart-Harris, R. *et al.* Trial of Psilocybin versus Escitalopram for Depression. *N. Engl.*
1876 *J. Med.* **384**, 1402–1411 (2021).
- 1877 13. de Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J.
1878 & Gobbi, G. Hallucinogens in mental health: Preclinical and clinical studies on LSD,
1879 psilocybin, MDMA, and ketamine. *J. Neurosci.* **41**, 891–900 (2021).
- 1880 14. Mitchell, J. M. *et al.* MDMA-assisted therapy for severe PTSD: a randomized, double-
1881 blind, placebo-controlled phase 3 study. *Nat. Med.* **27**, 1025–1033 (2021).
- 1882 15. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M.
1883 W., Finan, P. H. & Griffiths, R. R. Effects of Psilocybin-Assisted Therapy on Major
1884 Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry* (2020)
1885 doi:10.1001/jamapsychiatry.2020.3285.
- 1886 16. Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for
1887 treatment of psychiatric disorders. *Nat. Rev. Neurosci.* **21**, 611–624 (2020).
- 1888 17. Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M. & Olson, D. E. Psychedelics and
1889 Other Psychoplastogens for Treating Mental Illness. *Front. Psychiatry* **12**, 1691 (2021).
- 1890 18. Luppi, A. I. *et al.* Consciousness-specific dynamic interactions of brain integration and
1891 functional diversity. *Nat. Commun.* **10**, (2019).
- 1892 19. Huang, Z., Zhang, J., Wu, J., Mashour, G. A. & Hudetz, A. G. Temporal circuit of
1893 macroscale dynamic brain activity supports human consciousness. *Sci. Adv.* **6**, 87–98
1894 (2020).
- 1895 20. Campbell, J. M., Huang, Z., Zhang, J., Wu, X., Qin, P., Northoff, G., Mashour, G. A. &
1896 Hudetz, A. G. Pharmacologically informed machine learning approach for identifying
1897 pathological states of unconsciousness via resting-state fMRI. *NeuroImage* **206**,
1898 116316 (2020).
- 1899 21. Luppi, A. I. *et al.* Connectome Harmonic Decomposition of Human Brain Dynamics
1900 Reveals a Landscape of Consciousness. *bioRxiv* (2020)
1901 doi:10.1101/2020.08.10.244459.
- 1902 22. Sarasso, S. *et al.* Consciousness and complexity during unresponsiveness induced by
1903 propofol, xenon, and ketamine. *Curr. Biol.* **25**, 3099–3105 (2015).
- 1904 23. Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K. &
1905 Muthukumaraswamy, S. D. Increased spontaneous MEG signal diversity for
1906 psychoactive doses of ketamine, LSD and psilocybin. *Sci. Rep.* **7**, 46421 (2017).
- 1907 24. Li, D. & Mashour, G. A. Cortical dynamics during psychedelic and anesthetized states
1908 induced by ketamine. *NeuroImage* **196**, 32–40 (2019).
- 1909 25. Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griffiths, R. R. Classic psychedelics:
1910 An integrative review of epidemiology, therapeutics, mystical experience, and brain
1911 network function. *Pharmacol. Ther.* **197**, 83–102 (2019).
- 1912 26. Carhart-Harris, R. L. & Goodwin, G. M. The Therapeutic Potential of Psychedelic
1913 Drugs: Past, Present, and Future. *Neuropsychopharmacol. Off. Publ. Am. Coll.*
1914 *Neuropsychopharmacol.* **42**, 2105–2113 (2017).
- 1915 27. Goulas, A., Changeux, J. P., Wagstyl, K., Amunts, K., Palomero-Gallagher, N. &
1916 Hilgetag, C. C. The natural axis of transmitter receptor distribution in the human
1917 cerebral cortex. *Proc. Natl. Acad. Sci. U. S. A.* **118**, (2021).
- 1918 28. Zilles, K. & Palomero-Gallagher, N. Multiple transmitter receptors in regions and layers
1919 of the human cerebral cortex. *Front. Neuroanat.* **11**, 78 (2017).
- 1920 29. Suárez, L. E., Markello, R. D., Betzel, R. F. & Misic, B. Linking Structure and Function
1921 in Macroscale Brain Networks. *Trends Cogn. Sci.* **24**, 302–315 (2020).

- 1922 30. Shine, J. M. Neuromodulatory Influences on Integration and Segregation in the Brain.
1923 *Trends Cogn. Sci.* **23**, 572–583 (2019).
- 1924 31. Hansen, J. Y. *et al.* Mapping neurotransmitter systems to the structural and functional
1925 organization of the human neocortex. *Nat. Neurosci.* (**accepted**), 1–26 (2022).
- 1926 32. Trapani, G., Altomare, C., Sanna, E., Biggio, G. & Liso, G. Propofol in Anesthesia.
1927 Mechanism of Action, Structure-Activity Relationships, and Drug Delivery. *Curr. Med.*
1928 *Chem.* **7**, 249–271 (2000).
- 1929 33. Jurd, R. *et al.* General anesthetic actions *in vivo* strongly attenuated by a point mutation
1930 in the GABA_A receptor $\beta 3$ subunit. *FASEB J.* **17**, 250–252 (2003).
- 1931 34. Yip, G. M. S. *et al.* A propofol binding site on mammalian GABA_A receptors identified
1932 by photolabeling. *Nat. Chem. Biol.* **9**, 715–720 (2013).
- 1933 35. Nishikawa, K. & Harrison, N. L. The Actions of Sevoflurane and Desflurane on the γ -
1934 Aminobutyric Acid Receptor Type A: Effects of TM2 Mutations in the α and β Subunits.
1935 *Anesthesiology* **99**, 678–684 (2003).
- 1936 36. Wu, J., Harata, N. & Akaike, N. Potentiation by sevoflurane of the gamma-aminobutyric
1937 acid-induced chloride current in acutely dissociated CA1 pyramidal neurones from rat
1938 hippocampus. *Br. J. Pharmacol.* **119**, 1013–1021 (1996).
- 1939 37. Hirota, K. & Roth, S. H. Sevoflurane modulates both GABAA and GABAB receptors in
1940 area CA1 of rat hippocampus. *Br. J. Anaesth.* **78**, 60–65 (1997).
- 1941 38. Jenkins, A., Franks, N. P. & Lieb, W. R. Effects of temperature and volatile anesthetics
1942 on GABA(A) receptors. *Anesthesiology* **90**, 484–491 (1999).
- 1943 39. Campagna, J. A., Miller, K. W. & Forman, S. A. Mechanisms of actions of inhaled
1944 anesthetics. *N. Engl. J. Med.* **348**, 2110–2124 (2003).
- 1945 40. Domino, E. F. Taming the ketamine tiger. *Anesthesiology* **113**, 678–684 (2010).
- 1946 41. Domino, E. F., Chodoff, P. & Corssen, G. Pharmacologic effects of CI-581, a new
1947 dissociative anesthetic, in man. *Clin. Pharmacol. Ther.* **6**, 279–291 (1965).
- 1948 42. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D.,
1949 Heninger, G. R., Bowers, M. B. & Charney, D. S. Subanesthetic Effects of the
1950 Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic,
1951 Perceptual, Cognitive, and Neuroendocrine Responses. *Arch. Gen. Psychiatry* **51**,
1952 199–214 (1994).
- 1953 43. Mashour, G. A. Top-down mechanisms of anesthetic-induced unconsciousness. *Front.*
1954 *Syst. Neurosci.* **8**, (2014).
- 1955 44. Olney, J. W., Newcomer, J. W. & Farber, N. B. NMDA receptor hypofunction model of
1956 schizophrenia. *J. Psychiatr. Res.* **33**, 523–533 (1999).
- 1957 45. Li, L. & Vlisides, P. E. Ketamine: 50 Years of Modulating the Mind. *Front. Hum.*
1958 *Neurosci.* **10**, (2016).
- 1959 46. Nichols, D. E. Psychedelics. *Pharmacol. Rev.* **68**, 264–355 (2016).
- 1960 47. Glennon, R. A., Titeler, M. & McKenney, J. D. Evidence for 5-HT₂ involvement in the
1961 mechanism of action of hallucinogenic agents. *Life Sci.* **35**, 2505–2511 (1984).
- 1962 48. Nichols, D. E. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide
1963 (LSD). *ACS Chem. Neurosci.* **9**, 2331–2343 (2018).
- 1964 49. Nichols, D. E. Hallucinogens. *Pharmacol. Ther.* **101**, 131–181 (2004).
- 1965 50. Sleigh, J., Harvey, M., Voss, L. & Denny, B. Ketamine – More mechanisms of action
1966 than just NMDA blockade. *Trends Anaesth. Crit. Care* **4**, 76–81 (2014).
- 1967 51. Spindler, L. R. B. *et al.* Dopaminergic brainstem disconnection is common to
1968 pharmacological and pathological consciousness perturbation. *Proc. Natl. Acad. Sci. U.*
1969 *S. A.* **118**, e2026289118 (2021).
- 1970 52. Lawn, T., Dipasquale, O., Vamvakas, A., Tsougos, I., Mehta, M. A. & Howard, M. A.
1971 Differential contributions of serotonergic and dopaminergic functional connectivity to the
1972 phenomenology of LSD. *Psychopharmacology (Berl.)* (2022) doi:10.1007/S00213-022-
1973 06117-5.
- 1974 53. Ballentine, G., Friedman, S. F. & Bzdok, D. Trips and neurotransmitters: Discovering
1975 principled patterns across 6850 hallucinogenic experiences. *Sci. Adv.* **8**, eabl6989
1976 (2022).

- 1977 54. Sydnor, V. J. *et al.* Neurodevelopment of the association cortices: Patterns,
1978 mechanisms, and implications for psychopathology. *Neuron* (2021)
1979 doi:10.1016/j.neuron.2021.06.016.
- 1980 55. Huntenburg, J. M., Bazin, P. L., Goulas, A., Tardif, C. L., Villringer, A. & Margulies, D.
1981 S. A Systematic Relationship Between Functional Connectivity and Intracortical Myelin
1982 in the Human Cerebral Cortex. *Cereb. Cortex* **27**, 981–997 (2017).
- 1983 56. Valk, S. L. *et al.* Genetic and phylogenetic uncoupling of structure and function in
1984 human transmodal cortex. *bioRxiv* **5**, 2021.06.08.447522 (2021).
- 1985 57. Margulies, D. S. *et al.* Situating the default-mode network along a principal gradient of
1986 macroscale cortical organization. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 12574–12579
1987 (2016).
- 1988 58. Burt, J. B., Demirtaş, M., Eckner, W. J., Navejar, N. M., Ji, J. L., Martin, W. J.,
1989 Bernacchia, A., Anticevic, A. & Murray, J. D. Hierarchy of transcriptomic specialization
1990 across human cortex captured by structural neuroimaging topography. *Nat. Neurosci.*
1991 **21**, 1251–1259 (2018).
- 1992 59. Hansen, J. Y., Markello, R. D., Vogel, J. W., Seidlitz, J., Bzdok, D. & Misic, B. Mapping
1993 gene transcription and neurocognition across human neocortex. *Nat. Hum. Behav.* 1–
1994 11 (2021) doi:10.1038/s41562-021-01082-z.
- 1995 60. Carhart-Harris, R. L. *et al.* Neural correlates of the LSD experience revealed by
1996 multimodal neuroimaging. *Proc. Natl. Acad. Sci.* **113**, 201518377 (2016).
- 1997 61. Carhart-Harris, R. L. *et al.* Neural correlates of the psychedelic state as determined by
1998 fMRI studies with psilocybin. *Proc. Natl. Acad. Sci.* **109**, 2138–2143 (2012).
- 1999 62. Viol, A., Palhano-Fontes, F., Onias, H., De Araujo, D. B. & Viswanathan, G. M.
2000 Shannon entropy of brain functional complex networks under the influence of the
2001 psychedelic Ayahuasca. *Sci. Rep.* **7**, (2017).
- 2002 63. Carhart-Harris, R. L. *et al.* The Effects of Acutely Administered 3,4-
2003 Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy
2004 Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent
2005 Resting State Functional Connectivity. *Biol. Psychiatry* **78**, 554–562 (2015).
- 2006 64. Dandash, O., Harrison, B. J., Adapa, R., Gaillard, R., Giorlando, F., Wood, S. J.,
2007 Fletcher, P. C. & Fornito, A. Selective Augmentation of Striatal Functional Connectivity
2008 Following NMDA Receptor Antagonism: Implications for Psychosis.
2009 *Neuropsychopharmacology* **40**, 622–631 (2015).
- 2010 65. Esposito, R. *et al.* Acute Effects of Modafinil on Brain Resting State Networks in Young
2011 Healthy Subjects. *PLoS ONE* **8**, (2013).
- 2012 66. Ranft, A. *et al.* Neural Correlates of Sevoflurane-induced Unconsciousness Identified
2013 by Simultaneous Functional Magnetic Resonance Imaging and
2014 Electroencephalography. *Anesthesiology* **125**, 861–872 (2016).
- 2015 67. Stamatakis, E. A., Adapa, R. M., Absalom, A. R. & Menon, D. K. Changes in resting
2016 neural connectivity during propofol sedation. *PloS One* **5**, e14224 (2010).
- 2017 68. Naci, L., Sinai, L. & Owen, A. M. Detecting and interpreting conscious experiences in
2018 behaviorally non-responsive patients. *NeuroImage* **145**, 304–313 (2017).
- 2019 69. Dipasquale, O. *et al.* Unravelling the effects of methylphenidate on the dopaminergic
2020 and noradrenergic functional circuits. doi:10.1038/s41386-020-0724-x.
- 2021 70. Dipasquale, O., Selvaggi, P., Veronese, M., Gabay, A. S., Turkheimer, F. & Mehta, M.
2022 A. Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel,
2023 multimodal analytical approach informed by PET to study the pharmacodynamic
2024 response of the brain under MDMA. (2019) doi:10.1016/j.neuroimage.2019.04.007.
- 2025 71. Kringelbach, M. L., Cruzat, J., Cabral, J., Knudsen, G. M., Carhart-Harris, R., Whybrow,
2026 P. C., Logothetis, N. K. & Deco, G. Dynamic coupling of whole-brain neuronal and
2027 neurotransmitter systems. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 9566–9576 (2020).
- 2028 72. Deco, G., Cruzat, J., Cabral, J., Whybrow, P. C., Logothetis, N. K. & Kringelbach, M. L.
2029 Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains
2030 Non-linear Functional Effects of LSD. *Curr. Biol.* **28**, 3065–3074 (2018).

73. Burt, J., Preller, K., Demirtaş, M., Ji, J. L., Krystal, J., Vollenweider, F., Anticevic, A. & Murray, J. Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD. *eLife* **10**, (2021).
74. Parker Singleton, S. A., Luppi B, A. I., Carhart-Harris D, R. L., Cruzat, J. F., Roseman, L. D., Deco, G. G., Kringelbach K, M. L., Stamatakis B, E. A. & Kuceyeski, A. A. Psychedelics Flatten the brain's energy landscape: evidence from receptor-informed network control theory. *bioRxiv* 2021.05.14.444193 (2021) doi:10.1101/2021.05.14.444193.
75. Bonhomme, V. *et al.* Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers. *Anesthesiology* **125**, 873–888 (2016).
76. Lee, U., Ku, S., Noh, G., Baek, S., Choi, B. & Mashour, G. A. Disruption of frontal-parietal communication by ketamine, propofol, and sevoflurane. *Anesthesiology* **118**, 1264–75 (2013).
77. Kaller, S. *et al.* Test–retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. *Eur. J. Nucl. Med. Mol. Imaging* **44**, (2017).
78. Sandiego, C. M., Gallezot, J.-D., Lim, K., Ropchan, J., Lin, S., Gao, H., Morris, E. D. & Cosgrove, K. P. Reference region modeling approaches for amphetamine challenge studies with [11C]FLB 457 and PET. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **35**, 623–629 (2015).
79. Slifstein, M. *et al.* Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA Psychiatry* **72**, 316–324 (2015).
80. Smith, C. T. *et al.* Partial-volume correction increases estimated dopamine D2-like receptor binding potential and reduces adult age differences. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **39**, 822–833 (2019).
81. Zakariaeiz, Y. *et al.* Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* **44**, 2205–2211 (2019).
82. Dukart, J. *et al.* Cerebral blood flow predicts differential neurotransmitter activity. *Sci. Rep.* **8**, 4074 (2018).
83. Sanchez-Rangel, E., Gallezot, J.-D., Yeckel, C. W., Lam, W., Belfort-DeAguiar, R., Chen, M.-K., Carson, R. E., Sherwin, R. & Hwang, J. J. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB. *Int. J. Obes.* **44**, 964–967 (2020).
84. Ding, Y.-S. *et al.* PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT. *Synap. N. Y. N* **64**, 30–38 (2010).
85. Belfort-DeAguiar, R., Gallezot, J.-D., Hwang, J. J., Elshafie, A., Yeckel, C. W., Chan, O., Carson, R. E., Ding, Y.-S. & Sherwin, R. S. Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia. *J. Clin. Endocrinol. Metab.* **103**, 2244–2252 (2018).
86. Li, C. R. *et al.* Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine. *NeuroImage* **86**, 306–310 (2014).
87. Savli, M. *et al.* Normative database of the serotonergic system in healthy subjects using multi-tracer PET. *NeuroImage* **63**, 447–459 (2012).
88. Gallezot, J.-D. *et al.* Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **30**, 196–210 (2010).
89. Matuskey, D. *et al.* Reductions in brain 5-HT1B receptor availability in primarily cocaine-dependent humans. *Biol. Psychiatry* **76**, 816–822 (2014).
90. Murrough, J. W. *et al.* The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. *Arch. Gen. Psychiatry* **68**, 892–900 (2011).

91. Pittenger, C. *et al.* OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT_{1B} receptor binding. *J. Affect. Disord.* **196**, 87–96 (2016).
92. Saricicek, A. *et al.* Test-retest reliability of the novel 5-HT_{1B} receptor PET radioligand [11C]P943. *Eur. J. Nucl. Med. Mol. Imaging* **42**, 468–477 (2015).
93. Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N. & Knudsen, G. M. A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System. *J. Neurosci.* **37**, 120 (2017).
94. Radhakrishnan, R. *et al.* In vivo 5-HT₆ and 5-HT_{2A} receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. *Psychiatry Res. Neuroimaging* **295**, 111007 (2020).
95. Radhakrishnan, R. *et al.* Age-Related Change in 5-HT₆ Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET. *J. Nucl. Med.* **59**, 1445–1450 (2018).
96. Hillmer, A. T. *et al.* Imaging of cerebral $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. *NeuroImage* **141**, 71–80 (2016).
97. Baldassarri, S. R. *et al.* Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study. *Nicotine Tob. Res. Off. J. Soc. Res. Nicotine Tob.* **20**, 425–433 (2018).
98. Naganawa, M. *et al.* First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. *J. Nucl. Med. Off. Publ. Soc. Nucl. Med.* **62**, 553–560 (2021).
99. Bedard, M.-A., Aghourian, M., Legault-Denis, C., Postuma, R. B., Soucy, J.-P., Gagnon, J.-F., Pelletier, A. & Montplaisir, J. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with 18F-FEOBV. *Sleep Med.* **58**, 35–41 (2019).
100. Aghourian, M., Legault-Denis, C., Soucy, J.-P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P. & Bédard, M.-A. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. *Mol. Psychiatry* **22**, 1531–1538 (2017).
101. Smart, K., Cox, S. M. L., Scala, S. G., Tippler, M., Jaworska, N., Boivin, M., Séguin, J. R., Benkelfat, C. & Leyton, M. Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors. *Eur. J. Nucl. Med. Mol. Imaging* **46**, 1179–1183 (2019).
102. DuBois, J. M. *et al.* Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET. *Eur. J. Nucl. Med. Mol. Imaging* **43**, 152–162 (2016).
103. Galovic, M. *et al.* In vivo NMDA receptor function in people with NMDA receptor antibody encephalitis. 2021.12.04.21267226 Preprint at <https://doi.org/10.1101/2021.12.04.21267226> (2021).
104. Galovic, M. *et al.* Validation of a combined image derived input function and venous sampling approach for the quantification of [18F]GE-179 PET binding in the brain. *NeuroImage* **237**, 118194 (2021).
105. Nørgaard, M., Beliveau, V., Ganz, M., Svarer, C., Pinborg, L., Keller, S., Jensen, P., Greve, D. & Knudsen, G. A High-Resolution In Vivo Atlas of the Human Brain's Benzodiazepine Binding Site of GABA A Receptors. *NeuroImage* **232**, 117878 (2021).
106. Gallezot, J.-D. *et al.* Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H₃ receptor occupancy by PF-03654746. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **37**, 1095–1107 (2017).
107. D'Souza, D. C. *et al.* Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. *Biol. Psychiatry Cogn. Neurosci. Neuroimaging* **1**, 60–67 (2016).

108. Neumeister, A. *et al.* Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. *Alcohol. Clin. Exp. Res.* **36**, 2104–2109 (2012).
109. Normandin, M. D. *et al.* Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. *J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab.* **35**, 1313–1322 (2015).
110. Ranganathan, M. *et al.* Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. *Biol. Psychiatry* **79**, 997–1005 (2016).
111. Kantonen, T. *et al.* Interindividual variability and lateralization of μ -opioid receptors in the human brain. *NeuroImage* **217**, 116922 (2020).
112. Schaefer, A., Kong, R., Gordon, E. M., Laumann, T. O., Zuo, X.-N., Holmes, A. J., Eickhoff, S. B. & Yeo, B. T. T. Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic Functional Connectivity MRI. *Cereb. Cortex* **28**, 3095–3114 (2018).
113. Hansen, J. Y. *et al.* Molecular and connectomic vulnerability shape cross-disorder cortical abnormalities. *bioRxiv* 2022.01.21.476409 (2022) doi:10.1101/2022.01.21.476409.
114. Betzel, R. F. & Bassett, D. S. Specificity and robustness of long-distance connections in weighted, interareal connectomes. *Proc Natl Acad Sci USA* (2018) doi:10.1073/pnas.1720186115.
115. Roberts, J. A., Perry, A., Lord, A. R., Roberts, G., Mitchell, P. B., Smith, R. E., Calamante, F. & Breakspear, M. The contribution of geometry to the human connectome. *NeuroImage* **124**, 379–393 (2016).
116. Stiso, J. & Bassett, D. S. Spatial Embedding Imposes Constraints on Neuronal Network Architectures. *Trends Cogn. Sci.* **22**, 1127–1142 (2018).
117. Wold, S., Josefson, M., Gottfries, J. & Linusson, A. The utility of multivariate design in PLS modeling. *J. Chemom.* **18**, 156–165 (2004).
118. McIntosh, A. R. & Lobaugh, N. J. Partial least squares analysis of neuroimaging data: applications and advances. *NeuroImage* **23 Suppl 1**, S250-263 (2004).
119. Krishnan, A., Williams, L. J., McIntosh, A. R. & Abdi, H. Partial Least Squares (PLS) methods for neuroimaging: A tutorial and review. *NeuroImage* **56**, 455–475 (2011).
120. McIntosh, A. R. & Mišić, B. Multivariate Statistical Analyses for Neuroimaging Data. *Annu. Rev. Psychol.* **64**, 499–525 (2013).
121. Markello, R. D. & Misic, B. Comparing spatial null models for brain maps. *NeuroImage* **236**, 118052 (2021).
122. Váša, F. & Mišić, B. M. *Null Models in Network Neuroscience*.
123. Váša, F. *et al.* Adolescent tuning of association cortex in human structural brain networks. *Cereb. Cortex* **28**, 281–294 (2018).
124. Alexander-Bloch, A. F., Shou, H., Liu, S., Satterthwaite, T. D., Glahn, D. C., Shinohara, R. T., Vandekar, S. N. & Raznahan, A. On testing for spatial correspondence between maps of human brain structure and function. *NeuroImage* **178**, 540–551 (2018).
125. Yeo, B. T. T. *et al.* The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J. Neurophysiol.* **106**, 1125–1165 (2011).
126. Hill, J., Inder, T., Neil, J., Dierker, D., Harwell, J. & Van Essen, D. Similar patterns of cortical expansion during human development and evolution. *Proc. Natl. Acad. Sci.* **107**, 13135–13140 (2010).
127. Hawrylycz, M. J. *et al.* An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* **489**, 391–399 (2012).
128. Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C. & Wager, T. D. Large-scale automated synthesis of human functional neuroimaging data. *Nat. Methods* **8**, 665–670 (2011).
129. Luppi, A. I. *et al.* A synergistic core for human brain evolution and cognition. *Nat. Neurosci.* **25**, 771–782 (2022).
130. Larivière, S. *et al.* The ENIGMA Toolbox: multiscale neural contextualization of multisite neuroimaging datasets. *Nat. Methods* 2021 187 **18**, 698–700 (2021).

131. Sun, D. *et al.* Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. *Mol. Psychiatry* **25**, 1822–1834 (2020).
132. Hoogman, M. *et al.* Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. *Am. J. Psychiatry* **176**, 531–542 (2019).
133. van Rooij, D. *et al.* Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group. *Am. J. Psychiatry* **175**, 359–369 (2018).
134. Whelan, C. D. *et al.* Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. *Brain J. Neurol.* **141**, 391–408 (2018).
135. Schmaal, L. *et al.* Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. *Mol. Psychiatry* **22**, 900–909 (2017).
136. Boedhoe, P. S. W. *et al.* Cortical Abnormalities Associated With Pediatric and Adult Obsessive-Compulsive Disorder: Findings From the ENIGMA Obsessive-Compulsive Disorder Working Group. *Am. J. Psychiatry* **175**, 453–462 (2018).
137. van Erp, T. G. M. *et al.* Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. *Biol. Psychiatry* **84**, 644–654 (2018).
138. Hibar, D. P. *et al.* Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. *Mol. Psychiatry* **23**, 932–942 (2018).
139. Laansma, M. A. *et al.* International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. *Mov. Disord.* **36**, 2583–2594 (2021).
140. Vos de Wael, R. *et al.* BrainSpace: a toolbox for the analysis of macroscale gradients in neuroimaging and connectomics datasets. *Commun. Biol.* **3**, (2020).
141. Paquola, C. *et al.* A multi-scale cortical wiring space links cellular architecture and functional dynamics in the human brain. *PLOS Biol.* **18**, e3000979 (2020).
142. Cammoun, L., Gigandet, X., Meskaldji, D., Thiran, J. P., Sporns, O., Do, K. Q., Maeder, P., Meuli, R. & Hagmann, P. Mapping the human connectome at multiple scales with diffusion spectrum MRI. *J. Neurosci. Methods* **203**, 386–397 (2012).
143. Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S. & Liechti, M. E. ARTICLE Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. doi:10.1038/s41386-019-0569-3.
144. Viol, A., Palhano-Fontes, F., Onias, H., de Araujo, D. B., Hövel, P. & Viswanathan, G. M. Characterizing complex networks using entropy-degree diagrams: Unveiling changes in functional brain connectivity induced by Ayahuasca. *Entropy* **21**, (2019).
145. Luppi, A. I., Carhart-Harris, R. L., Roseman, L., Pappas, I., Menon, D. K. & Stamatakis, E. A. LSD alters dynamic integration and segregation in the human brain. *NeuroImage* **227**, 117653 (2021).
146. Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G. & Carhart-Harris, R. L. Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD. *Sci. Rep.* **7**, 1–18 (2017).
147. Lord, L. D. *et al.* Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. *NeuroImage* **199**, 127–142 (2019).
148. Scharfner, M., Seth, A., Noirhomme, Q., Boly, M., Bruno, M. A., Laureys, S. & Barrett, A. Complexity of multi-dimensional spontaneous EEG decreases during propofol induced general anaesthesia. *PLoS ONE* **10**, (2015).
149. Toker, D. *et al.* Consciousness is supported by near-critical cortical electrodynamics. doi:10.1073/pnas.XXXXXXXX.
150. Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. *Pharmacol. Rev.* **71**, 316–344 (2019).

- 2249 151. Varley, T. F., Luppi, A. I., Pappas, I., Naci, L., Adapa, R., Owen, A. M., Menon, D. K. &
2250 Stamatakis, E. A. Consciousness & Brain Functional Complexity in Propofol
2251 Anaesthesia. *Sci. Rep.* **10**, 1–13 (2020).
- 2252 152. Varley, T. F., Craig, M. M., Adapa, R., Finoia, P., Williams, G., Allanson, J., Pickard, J.,
2253 Menon, D. K. & Stamatakis, E. A. Fractal dimension of cortical functional connectivity
2254 networks & severity of disorders of consciousness. *PLoS ONE* **15**, 1–20 (2020).
- 2255 153. Varley, T. F., Carhart-Harris, R., Roseman, L., Menon, D. K. & Stamatakis, E. A.
2256 Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical
2257 brain activity in spatial and temporal domains. *NeuroImage* **220**, (2020).
- 2258 154. Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J. & Carhart-
2259 Harris, R. L. LSD-induced entropic brain activity predicts subsequent personality
2260 change. *Hum. Brain Mapp.* **37**, 3203–3213 (2016).
- 2261 155. Boveroux, P., Vanhaudenhuyse, A. & Phillips, C. Breakdown of within- and between-
2262 network Resting State during Propofol-induced Loss of Consciousness. *Anesthesiology*
2263 **113**, 1038–1053 (2010).
- 2264 156. Wu, H. *et al.* Anterior precuneus related to the recovery of consciousness. *NeuroImage*
2265 *Clin.* **33**, 102951 (2022).
- 2266 157. Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Jose, A. C. S., Crippa, A. S., Hallak, J.
2267 E. C., Ribeiro, S. & De Araujo, D. B. The psychedelic state induced by Ayahuasca
2268 modulates the activity and connectivity of the Default Mode Network. *PLoS ONE* **10**,
2269 (2015).
- 2270 158. Girn, M., Roseman, L., Bernhardt, B., Smallwood, J., Carhart-Harris, R. & Spreng, R. N.
2271 LSD flattens the functional hierarchy of the human brain. *bioRxiv* 2020.05.01.072314
2272 (2020) doi:10.1101/2020.05.01.072314.
- 2273 159. Demirtaş, M. *et al.* Hierarchical Heterogeneity across Human Cortex Shapes Large-
2274 Scale Neural Dynamics. *Neuron* **101**, 1181–1194.e13 (2019).
- 2275 160. Beul, S. F. & Hilgetag, C. C. Neuron density fundamentally relates to architecture and
2276 connectivity of the primate cerebral cortex. *NeuroImage* **189**, 777–792 (2019).
- 2277 161. Baum, G. L. *et al.* Development of structure–function coupling in human brain networks
2278 during youth. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 771–778 (2020).
- 2279 162. Doss, M. K., May, D. G., Johnson, M. W., Clifton, J. M., Hedrick, S. L., Prisinzano, T.
2280 E., Griffiths, R. R. & Barrett, F. S. The Acute Effects of the Atypical Dissociative
2281 Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. *Sci. Rep.* **10**,
2282 16392 (123AD).
- 2283 163. Akeju, O. *et al.* Disruption of thalamic functional connectivity is a neural correlate of
2284 dexmedetomidine-induced unconsciousness. *eLife* **3**, (2014).
- 2285 164. Guldenmund, P. *et al.* Brain functional connectivity differentiates dexmedetomidine
2286 from propofol and natural sleep. *BJA Br. J. Anaesth.* **119**, 674–684 (2017).
- 2287 165. Nelson, L. E., Lu, J., Guo, T., Saper, C. B., Franks, N. P. & Maze, M. The $\alpha 2$ -
2288 adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting
2289 pathway to exert its sedative effects. *Anesthesiology* **98**, 428–436 (2003).
- 2290 166. Van de Bittner, G. C., Ricq, E. L. & Hooker, J. M. A philosophy for CNS radiotracer
2291 design. *Acc. Chem. Res.* **47**, 3127–3134 (2014).
- 2292 167. Elsinga, P. H., Hatano, K. & Ishiwata, K. PET tracers for imaging of the dopaminergic
2293 system. *Curr. Med. Chem.* **13**, 2139–2153 (2006).
- 2294 168. Redinbaugh, M. J., Phillips, J. M., Kambi, N. A., Mohanta, S., Andryk, S., Dooley, G. L.,
2295 Afrasiabi, M., Raz, A. & Saalman, Y. B. Thalamus modulates consciousness via layer-
2296 specific control of cortex. *Neuron* **106**, 66–75.e12 (2020).
- 2297 169. Tasserie, J., Uhrig, L., Sitt, J. D., Manasova, D., Dupont, M., Dehaene, S. & Jarraya, B.
2298 Deep brain stimulation of the thalamus restores signatures of consciousness in a
2299 nonhuman primate model. *Sci Adv* **8**, 5547 (2022).
- 2300 170. Barttfeld, P., Bekinschtein, T. A., Salles, A., Stamatakis, E. A., Adapa, R., Menon, D. K.
2301 & Sigman, M. Factoring the brain signatures of anesthesia concentration and level of
2302 arousal across individuals. *NeuroImage Clin.* **9**, 385–391 (2015).

171. Preller, K. H. *et al.* Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT_{2A} receptor. *eLife* **7**, (2018).
172. Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J. & Vollenweider, F. X. Effective connectivity changes in LSD-induced altered states of consciousness in humans. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 2743–2748 (2019).
173. Shine, J. M. The thalamus integrates the macrosystems of the brain to facilitate complex, adaptive brain network dynamics. *Prog. Neurobiol.* 101951 (2020) doi:10.1016/j.pneurobio.2020.101951.
174. Kringelbach, M. L. & Deco, G. Brain States and Transitions: Insights from Computational Neuroscience. *Cell Rep.* **32**, 108128 (2020).
175. Cofré, R., Herzog, R., Mediano, P. A. M., Piccinini, J., Rosas, F. E., Perl, Y. S. & Tagliazucchi, E. Whole-brain models to explore altered states of consciousness from the bottom up. *Brain Sci.* **10**, 1–29 (2020).
176. Deco, G. & Kringelbach, M. L. Great expectations: Using whole-brain computational connectomics for understanding neuropsychiatric disorders. *Neuron* **84**, 892–905 (2014).
177. Shine, J. M., Müller, E. J., Munn, B., Cabral, J., Moran, R. J. & Breakspear, M. Computational models link cellular mechanisms of neuromodulation to large-scale neural dynamics. *Nat. Neurosci.* 1–12 (2021) doi:10.1038/s41593-021-00824-6.
178. Herzog, R., Mediano, P. A. M., Rosas, F. E., Carhart-Harris, R., Perl, Y. S., Tagliazucchi, E. & Cofre, R. A mechanistic model of the neural entropy increase elicited by psychedelic drugs. *Sci. Rep.* **10**, 17725 (2020).
179. Luppi, A. I. *et al.* Whole-brain modelling identifies distinct but convergent paths to unconsciousness in anaesthesia and disorders of consciousness. *Commun. Biol.* **5**, 384 (2022).
180. Veselis, R. A., Feshchenko, V. A., Reinsel, R. A., Beattie, B. & Akhurst, T. J. Propofol and thiopental do not interfere with regional cerebral blood flow response at sedative concentrations. *Anesthesiology* **102**, 26–34 (2005).
181. Johnston, A. J., Steiner, L. A., Chatfield, D. A., Coleman, M. R., Coles, J. P., Al-Rawi, P. G., Menon, D. K. & Gupta, A. K. Effects of propofol on cerebral oxygenation and metabolism after head injury. *Br. J. Anaesth.* **91**, 781–786 (2003).
182. Hemmings, H. C., Akabas, M. H., Goldstein, P. A., Trudell, J. R., Orser, B. A. & Harrison, N. L. Emerging molecular mechanisms of general anesthetic action. *Trends Pharmacol. Sci.* **26**, 503–510 (2005).
183. Bademosi, A. T. *et al.* Trapping of Syntaxin1a in Presynaptic Nanoclusters by a Clinically Relevant General Anesthetic. *Cell Rep.* **22**, 427–440 (2018).
184. Wang, Y., Yu, T., Yuan, C., Yuan, J., Luo, Z., Pan, Y., Zhang, Y., Zhang, Y. & Yu, B. Effects of propofol on the dopamine, metabolites and GABAA receptors in media prefrontal cortex in freely moving rats. *Am J Transl Res* vol. 8 2301–2308 www.ajtr.org/ISSN:1943-8141/AJTR0024580 (2016).
185. Guo, J., Xu, K., Yin, J., Zhang, H., Yin, J. & Li, Y. Dopamine transporter in the ventral tegmental area modulates recovery from propofol anesthesia in rats. *J. Chem. Neuroanat.* **121**, 102083 (2022).
186. Naci, L. *et al.* Functional diversity of brain networks supports consciousness and verbal intelligence. *Sci. Rep.* **8**, 1–15 (2018).
187. Coppola, P. *et al.* Network dynamics scale with levels of awareness. *NeuroImage* 119128 (2022) doi:10.1016/J.NEUROIMAGE.2022.119128.
188. Kandeepan, S., Rudas, J., Gomez, F., Stojanoski, B., Valluri, S., Owen, A. M., Naci, L., Nichols, E. S. & Soddu, A. Modeling an auditory stimulated brain under altered states of consciousness using the generalized ising model. *NeuroImage* **223**, 117367 (2020).
189. Solt, K., Eger, E. I. & Raines, D. E. Differential modulation of human N-methyl-D-aspartate receptors by structurally diverse general anesthetics. *Anesth. Analg.* **102**, 1407–1411 (2006).

190. Hollmann, M. W., Liu, H. T., Hoenemann, C. W., Liu, W. H. & Durieux, M. E. Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. *Anesth. Analg.* **92**, 1182–1191 (2001).
191. Scheller, M., Bufler, J., Schneek, H., Kochs, E. & Franke, C. Isoflurane and sevoflurane interact with the nicotinic acetylcholine receptor channels in micromolar concentrations. *Anesthesiology* **86**, 118–127 (1997).
192. Alkire, M. T., McReynolds, J. R., Hahn, E. L. & Trivedi, A. N. Thalamic microinjection of nicotine reverses sevoflurane-induced loss of righting reflex in the rat. *Anesthesiology* **107**, 264–272 (2007).
193. Palanca, B. J. A., Avidan, M. S. & Mashour, G. A. Human neural correlates of sevoflurane-induced unconsciousness. *BJA Br. J. Anaesth.* **119**, 573–582 (2017).
194. Golkowski, D. *et al.* Coherence of BOLD signal and electrical activity in the human brain during deep sevoflurane anesthesia. *Brain Behav.* **7**, 1–8 (2017).
195. Golkowski, D. *et al.* Changes in Whole Brain Dynamics and Connectivity Patterns during Sevoflurane- and Propofol-induced Unconsciousness Identified by Functional Magnetic Resonance Imaging. *Anesthesiology* **130**, 898–911 (2019).
196. Luppi, A. I., Golkowski, D., Ranft, A., Ilg, R., Jordan, D., Menon, D. K. & Stamatakis, E. A. Brain network integration dynamics are associated with loss and recovery of consciousness induced by sevoflurane. *Hum. Brain Mapp.* (2021) doi:10.1002/hbm.25405.
197. Basso, L., Bönke, L., Aust, S., Gärtner, M., Heuser-Collier, I., Otte, C., Wingenfeld, K., Bajbouj, M. & Grimm, S. Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients. *J. Psychiatr. Res.* **123**, 1–8 (2020).
198. Phillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owøye, O., Batten, L. A. & Blier, P. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* **45**, 606–612 (2020).
199. Corlett, P. R., Honey, G. D. & Fletcher, P. C. Prediction error, ketamine and psychosis: An updated model. *J. Psychopharmacol. (Oxf.)* **30**, 1145–1155 (2016).
200. Moore, J. W. *et al.* Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia. *Cognit. Neuropsychiatry* **16**, 364–381 (2011).
201. Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS ONE* **5**, (2010).
202. Corlett, P. R. *et al.* Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: Linking cognition, brain activity, and psychosis. *Arch. Gen. Psychiatry* **63**, 611–621 (2006).
203. Marona-Lewicka, D., Kurrasch-Orbaugh, D. M., Selken, J. R., Cumbay, M. G., Lisnicchia, J. G. & Nichols, D. E. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine_{1A} receptor-mediated behavioral effects overlap its other properties in rats. *Psychopharmacology (Berl.)* **164**, 93–107 (2002).
204. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M. & Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. *CNS Neurosci. Ther.* **14**, 295–314 (2008).
205. Kraehenmann, R., Pokorny, D., Vollenweider, L., Preller, K. H., Pokorny, T., Seifritz, E. & Vollenweider, F. X. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. *Psychopharmacology (Berl.)* 1–16 (2017) doi:10.1007/s00213-017-4610-0.
206. Tagliazucchi, E. *et al.* Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. *Curr. Biol.* **26**, 1043–1050 (2016).
207. Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Bähler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* **9**, 3897–3902 (1998).
208. Passie, T., Seifert, J., Schneider, U. & Emrich, H. M. The pharmacology of psilocybin. *Addict. Biol.* **7**, 357–364 (2002).

209. González-Maeso, J. *et al.* Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. *Neuron* **53**, 439–452 (2007).
210. McKenna, D. J., Repke, D. B., Lo, L. & Peroutka, S. J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. *Neuropharmacology* **29**, 193–198 (1990).
211. Halberstadt, A. L., Koedood, L., Powell, S. B. & Geyer, M. A. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. *J. Psychopharmacol. Oxf. Engl.* **25**, 1548–1561 (2011).
212. Christian, S. T., Harrison, R., Quayle, E., Pagel, J. & Monti, J. The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent. *Biochem. Med.* **18**, 164–183 (1977).
213. Smythies, J. R., Morin, R. D. & Brown, G. B. Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry. *Biol. Psychiatry* **14**, 549–556 (1979).
214. Strassman, R. J. Human psychopharmacology of N,N-dimethyltryptamine. *Behav. Brain Res.* **73**, 121–124 (1995).
215. Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. & Kellner, R. Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale. *Arch. Gen. Psychiatry* **51**, 98–108 (1994).
216. Alamia, A., Timmermann, C., Vanrullen, R. & Carhart-Harris, R. L. DMT alters cortical travelling waves. *eLife* **9**, 1–16 (2020).
217. Timmermann, C. *et al.* Neural correlates of the DMT experience assessed with multivariate EEG. *Sci. Rep.* **9**, 16324 (2019).
218. Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., Andrade, E. N., Andrade, E. O. & Mash, D. C. Pharmacokinetics of Hoasca alkaloids in healthy humans. *J. Ethnopharmacol.* **65**, 243–256 (1999).
219. Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B. & Ruoho, A. E. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. *Science* **323**, 934–937 (2009).
220. Pierce, P. A. & Peroutka, S. J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. *Psychopharmacology (Berl.)* **97**, 118–122 (1989).
221. Ray, T. S. Psychedelics and the Human Receptorome. *PLoS ONE* **5**, e9019 (2010).
222. McKenna, D. J., Towers, G. H. & Abbott, F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. *J. Ethnopharmacol.* **10**, 195–223 (1984).
223. Buckholtz, N. S. & Boggan, W. O. Monoamine oxidase inhibition in brain and liver produced by β -carbolines: structure-activity relationships and substrate specificity. *Biochem. Pharmacol.* **26**, 1991–1996 (1977).
224. McKenna, D., Riba, J., McKenna, D. & Riba, J. New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca. *Curr Top. Behav Neurosci* **36**, 283–311 (2016).
225. Valle, M. *et al.* Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. *Eur. Neuropsychopharmacol.* **26**, 1161–1175 (2016).
226. van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L., Bosker, W. M., Bakker, K. & Ramaekers, J. G. Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT₂ and 5-HT₁ receptors. *PloS One* **7**, e40187 (2012).
227. Liechti, M. E. & Vollenweider, F. X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. *Hum. Psychopharmacol.* **16**, 589–598 (2001).
228. Schmid, Y., Gasser, P., Oehen, P. & Liechti, M. E. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. *J. Psychopharmacol. (Oxf.)* **35**, (2020).
229. Walpolá, I. C., Nest, T., Roseman, L., Erritzoe, D., Feilding, A., Nutt, D. J. & Carhart-Harris, R. L. Altered Insula Connectivity under MDMA. *Neuropsychopharmacology* **4235**, 2152–2162 (2017).

230. Ghahremani, D. G., Tabibnia, G., Monterosso, J., Helleman, G., Poldrack, R. A. & London, E. D. Effect of Modafinil on Learning and Task-Related Brain Activity in Methamphetamine-Dependent and Healthy Individuals. *Neuropsychopharmacology* **36**, 950–959 (2011).
231. Ishizuka, T., Murotani, T. & Yamatodani, A. Modanifil activates the histaminergic system through the orexinergic neurons. *Neurosci. Lett.* **483**, 193–196 (2010).
232. Volkow, N. D. *et al.* Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain: Clinical Implications. *JAMA J. Am. Med. Assoc.* **301**, 1148–1154 (2009).
233. Gass, J. T. & Foster Olive, M. Glutamatergic substrates of drug addiction and alcoholism. *Biochem. Pharmacol.* **75**, 218–265 (2008).
234. Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E. & Edgar, D. M. Dopaminergic role in stimulant-induced wakefulness. *J. Neurosci. Off. J. Soc. Neurosci.* **21**, 1787–1794 (2001).
235. Madras, B. K. *et al.* Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in Vitro. *J. Pharmacol. Exp. Ther.* **319**, 561–569 (2006).
236. Cera, N., Tartaro, A., Sensi, S. L. & Jan Stam, C. Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. *PLOS ONE* (2014) doi:10.1371/journal.pone.0107145.
237. Hannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E. & Ding, Y.-S. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. *Biol. Psychiatry* **68**, 854–860 (2010).
238. Rowley, H. L., Kulkarni, R. S., Gosden, J., Brammer, R. J., Hackett, D. & Heal, D. J. Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats. *J. Psychopharmacol. Oxf. Engl.* **28**, 254–269 (2014).
239. Koda, K., Ago, Y., Cong, Y., Kita, Y., Takuma, K. & Matsuda, T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. *J. Neurochem.* **114**, 259–270 (2010).
240. Williard, R. L., Middaugh, L. D., Zhu, H.-J. B. & Patrick, K. S. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. *Behav. Pharmacol.* **18**, 39–51 (2007).
241. Markowitz, J. S., DeVane, C. L., Pestreich, L. K., Patrick, K. S. & Muniz, R. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. *J. Child Adolesc. Psychopharmacol.* **16**, 687–698 (2006).
242. Volkow, N. D., Fowler, J. S., Wang, G., Ding, Y. & Gatley, S. J. Mechanism of action of methylphenidate: insights from PET imaging studies. *J. Atten. Disord.* **6 Suppl 1**, S31–43 (2002).
243. Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Hitzemann, R. & Pappas, N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am. J. Psychiatry* **155**, 1325–1331 (1998).
244. Whitfield-Gabrieli, S. & Nieto-Castanon, A. Conn: A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks. *Brain Connect.* **2**, 125–141 (2012).
245. Müller, F., Holze, F., Dolder, P., Ley, L., Vizeli, P., Soltermann, A., Liechti, M. E. & Borgwardt, S. MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. *Neuropsychopharmacology* (2020) doi:10.1038/s41386-020-00906-2.
246. Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L. & Petersen, S. E. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *NeuroImage* **59**, 2142–2154 (2012).

247. Behzadi Y, Restom K, Liau J, & Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. *NeuroImage* **37**, 90–101 (2007).
248. Andellini, M., Cannatà, V., Gazzellini, S., Bernardi, B. & Napolitano, A. Test-retest reliability of graph metrics of resting state MRI functional brain networks: A review. *J. Neurosci. Methods* **253**, 183–192 (2015).
249. Lydon-Staley, D. M., Ciric, R., Satterthwaite, T. D. & Bassett, D. S. Evaluation of confound regression strategies for the mitigation of micromovement artifact in studies of dynamic resting-state functional connectivity and multilayer network modularity. *Netw. Neurosci.* **3**, 427–454 (2019).
250. Power, J. D., Mitra, A., Laumann, T. O., Snyder, A. Z., Schlaggar, B. L. & Petersen, S. E. Methods to detect, characterize, and remove motion artifact in resting state fMRI. *NeuroImage* **84**, 320–341 (2014).
251. Murphy, K. & Fox, M. D. Towards a consensus regarding global signal regression for resting state functional connectivity MRI. *NeuroImage* **154**, 169–173 (2017).
252. Tanabe, S. *et al.* Altered Global Brain Signal during Physiologic, Pharmacologic, and Pathologic States of Unconsciousness in Humans and Rats. *Anesthesiology* 1392–1406 (2020) doi:10.1097/ALN.0000000000003197.
253. Thompson, P. M. *et al.* ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. *Transl. Psychiatry* **10**, 1–28 (2020).
254. Lioi, G., Gripon, V., Brahim, A., Rousseau, F. & Farrugia, N. Gradients of connectivity as graph Fourier bases of brain activity. *Netw. Neurosci.* **5**, 322–336 (2021).
255. Paquola, C. *et al.* Microstructural and functional gradients are increasingly dissociated in transmodal cortices. *PLoS Biol.* **17**, e3000284 (2019).